SanBio 
SANBIOINCORPORATED 
CLINICAL PROTOCOL 
TITLE: A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified 
Stem Cells (SB623) in Patients with Chronic Motor Deficit from Ischemic Stroke 
PROTOCOL#: 
Version: 5 
SPONSOR: 
SITE OF INVESTIGATION: 
PRINCIPAL MONITOR: 
UNBLINDED MEDICAL MONITOR: 
BLINDED MEDICAL MONITOR: 
SAFETY MONITOR: 
CLINICAL LABORATORY: SB-STR02 
Date: 05 January 2017 
SanBio, Incorporated 
231 S. Whisman Road 
Mountain View, CA 94041 USA 
Phone: + 1 650-625-8965 
Fax: + 1 650-625-8969 
Multi-Center 
Damien Bates, MD, PhD, FRACS (SanBio) 
Cindy Saacks, MD (INC Research) 
Alexander Shalaurov, MD (INC Research) 
Tim Smith, PharmD, BSN (ProPharma 
Group/PROSAR) 
Clinical laboratory testing will be performed 
centrally 
Principal Monitor Principal Investigator 
Damien Bates, MD, PhD, FRACS 
SanBio 
• Digitally signed by Damien 
Darnlen Bates Bates 
Date: 2017.01.0816:14:02 -08'00' 
Signature Date Investigator Name (Printed) 
Signature Date 
Investigator Statement 
I agree to abide by all the provisions set forth in the attached protocol. I also understand that these 
materials contain confidential information belonging to SanBio, Inc. Except as may be otherwise 
agreed to in writing, I agree to hold such information in confidence and not to disclose it to others 
(except where required by applicable law) nor use it for unauthorized purposes. In the event of actual 
or suspected breach of this obligation, SanBio, Inc. should be promptly notified. 

SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 2 of 86 TABLE OF CONTENTS  
1.0 PROTOCOL SYNOPSIS  ................................................................................................... 6 
2.0 BACKGROUND  ............................................................................................................... 14 
2.1 MEDICAL NEED ............................................................................................................................ 14 
2.2 TREATMENT OF ISCHEMIC STROKE  .............................................................................................. 14 
2.2.1  Current Therapies  ................................................................................................................. 14 
2.2.2  Time Course for Stable Stroke  .............................................................................................. 14 
2.2.3  Experimental Cellular Therapies  .......................................................................................... 14 
2.2.4  Stereotactic Surgery  .............................................................................................................. 15 
2.3 PROPERTIES OF SB623  .................................................................................................................. 15 
2.3.1  Summary of SB623 Cells Properties  ..................................................................................... 15 
2.3.2  Summary of Notch- 1 Gene Properties  .................................................................................. 16 
2.3.3  Preclinical Pharmacology Studies  ........................................................................................ 16 
3.0 OVERALL EXPERIENCE W ITH INVESTIGATIONAL PRODUCT  ..................... 17 
3.1 STUDY AGENT  .............................................................................................................................. 17 
3.2 PRECLINICAL PHARMACOLOGY  .................................................................................................... 17 
3.2.1  In Vitro  .................................................................................................................................. 17 
3.3 CLINICAL EXPERIENCE  ................................................................................................................. 17 
3.4 SUMMARY OF KNOWN AND POTENTIAL RISKS AND BENEFITS  .................................................... 19 
4.0 DESCRIPTION AND JUST IFICATION OF TREATME NT REGIMEN ................. 21 
4.1 DOSAGES  ...................................................................................................................................... 21 
4.2 JUSTIFICATION  .............................................................................................................................. 21 
5.0 STUDY PARAMETERS AND OBJECTIVES  .............................................................. 22 
5.1 PARAMETERS  ................................................................................................................................ 22 
5.1.1  Primary Efficacy Endpoint:  .................................................................................................. 22 
5.1.2  Secondary Efficacy Endpoints:  ............................................................................................. 22 
5.1.3  Safety Endpoints  .................................................................................................................... 22 
5.1.4  Exploratory Endpoints  .......................................................................................................... 22 
5.2 OBJECTIVES  .................................................................................................................................. 23 
5.2.1  Primary Objective  ................................................................................................................. 23 
5.2.2  Secondary Objectives  ............................................................................................................ 23 
6.0 SURGICAL AND IMPLANT ATION PROCEDURES  ................................................ 24 
7.0 PATIENT SELECTION  .................................................................................................. 26 
7.1 INCLUSION CRITERIA  .................................................................................................................... 26 
7.2 EXCLUSION CRITERIA  ................................................................................................................... 26 
8.0 INVESTIGATIONAL PLAN  .......................................................................................... 28 
8.1 OVERALL STUDY DESIGN  ............................................................................................................. 28 
8.2 DURATION OF PATIENT PARTICIPATION  ....................................................................................... 29 
9.0 STUDY ASSESSMENTS  ................................................................................................. 30 
9.1 SCHEDULE OF STUDY ACTIVITIES  ................................................................................................ 30 
9.2 PRE-STUDY EVALUATION AND BASELINE  .................................................................................... 36 
9.2.1  Visit 1: Screening, (Day -84 to - 22; Assessment Site)  ........................................................... 36 
9.3 BASELINE AND CONFIRMATION OF ELIGIBILITY  .......................................................................... 36 
9.3.1  Visit 2: Baseline (Day - 21 to - 2; Assessment Site)  ................................................................ 36 
9.3.2  Eligibility Confirmation  ........................................................................................................ 37 
9.4 SURGICAL ADMISSION (VISIT 3A: DAY -1; SURGICAL SITE) ....................................................... 37 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 3 of 86 9.5 RANDOMIZATION AND CELL ADMINISTRATION OR SHAM SURGERY (VISIT 3B: DAY 1; 
SURGICAL SITE) ....................................................................................................................................... 38 
9.6 VISIT 4: FOLLOW -UP PERIOD (STUDY DAY 2; SURGICAL SITE) ................................................... 38 
9.7 VISIT 5: FOLLOW -UP PERIOD (WEEK 1, STUDY DAY 8 ± 1; ASSESSMENT SITE).......................... 39 
9.8 VISIT 6: FOLLOW -UP PERIOD (MONTH 1, STUDY DAY 28 ± 7; ASSESSMENT SITE) ..................... 39 
9.9 VISIT 7: FOLLOW -UP PERIOD (MONTH 3, STUDY DAY 84 ± 7; ASSESSMENT SITE) ..................... 40 
9.10  VISIT 8: FOLLOW -UP PERIOD (MONTH 6, STUDY DAY 168 ± 7; ASSESSMENT SITE) ............... 40 
9.11  VISIT 9: FOLLOW -UP PERIOD (MONTH 9, STUDY DAY 252 ± 14; ASSESSMENT SITE) ............. 41 
9.12  VISIT 10/E ARL Y TERMINATION : FOLLOW -UP PERIOD (MONTH 12, STUDY DAY 336 ±  14; 
ASSESSMENT SITE) .................................................................................................................................. 41 
10.0  DESCRIPTION OF STUDY TREATMENT.............................................................. 43 
10.1  STUDY PRODUCT DESCRIPTION  ................................................................................................ 43 
10.2  STUDY PRODUCT PACKAGING AND LABELING  ......................................................................... 43 
10.3  STUDY PRODUCT SHIPMENT AND STORAGE  ............................................................................. 43 
10.4  PREPARATION AND ADMINISTRATION  ...................................................................................... 43 
10.5  STUDY PRODUCT ACCOUNTABILITY PROCEDURES  .................................................................. 44 
11.0  TREATMENT ASSIGNMENT  AND BLINDING  ..................................................... 45 
11.1  EMERGENCY UNBLINDING PROCEDURES  ................................................................................. 46 
12.0  CONCOMITANT MEDICATI ONS  ............................................................................ 47 
13.0  STUDY WITHDRAWAL/TERMINATION .............................................................. 48 
13.1  STUDY TERMINATION  ............................................................................................................... 48 
13.2  SITE TERMINATION  ................................................................................................................... 48 
13.3  PATIENT DISCONTINUATION  ..................................................................................................... 48 
13.4  PATIENTS LOST TO FOLLOW UP ................................................................................................ 48 
14.0  STOPPING RULES  ...................................................................................................... 49 
15.0  CLINICAL AND LABORAT ORY EVALUATIONS AND PROCEDURES  ......... 50 
15.1  MEDICAL HISTORY (INCLUDING STROKE HISTORY ) ................................................................ 50 
15.2  PHYSICAL EXAMINATION AND VITAL SIGNS  ............................................................................ 50 
15.3  SAFETY LABORATORY  .............................................................................................................. 50 
15.4  PREGNANCY TEST: SERUM OR URINE β-HCG ........................................................................... 50 
15.5  HLA  TYPING AND APOE4 AND BDNF  VAL66M ET GENOTYPING  ............................................ 50 
15.6  SERUM ANTI-HLA  ANTIBODIES  ............................................................................................... 51 
15.7  PBMC  SAMPLES  ....................................................................................................................... 51 
15.8  OCCULT MALIGNANCY  ............................................................................................................. 51 
15.9  CESD -R .................................................................................................................................... 51 
15.10  CLINICAL STROKE EVALUATIONS  ............................................................................................ 51 
15.11  PHYSIOTHERAPY  ....................................................................................................................... 53 
15.12  LEG ACTIVITY MONITORING  .................................................................................................... 53 
15.13  IMAGING (MRI),  CHEST X-RAY, CT,  AND ECG  ....................................................................... 53 
16.0  ADVERSE EVENTS  ..................................................................................................... 55 
16.1  GENERAL INFORMATION  ........................................................................................................... 55 
16.2  ADVERSE EVENT REPORTING PERIOD  ...................................................................................... 56 
16.3  RECORDING OF AES .................................................................................................................. 56 
16.4  ASSESSING RELATIONSHIP OF AE TO STUDY PRODUCT  ........................................................... 56 
16.5  REPORTING SERIOUS ADVERSE EVENTS  ................................................................................... 57 
16.6  FOLLOW -UP OF ADVERSE EVENTS  ............................................................................................ 57 
17.0  EXTERNAL DATA SAFETY MONITORING BOARD .......................................... 58 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 4 of 86 18.0  STATISTICAL METHODS  ......................................................................................... 59 
18.1  ANALYSIS POPULATIONS  .......................................................................................................... 59 
18.1.1  Efficacy Population  ............................................................................................................... 59 
18.1.2  Safety Population  .................................................................................................................. 59 
18.2  STATISTICAL ANALYSIS  ............................................................................................................ 59 
18.2.1  Analysis of Efficacy  ............................................................................................................... 59 
18.2.1.1  Primary Efficacy Analysis  .................................................................................. 59 
18.2.1.2  Secondary Efficacy Analyses  .............................................................................. 59 
18.2.1.3  Exploratory Efficacy Analyses  ........................................................................... 60 
18.2.1.4  Subgr oup Analysis  .............................................................................................. 61 
18.3  ANALYSIS OF SAFETY  ............................................................................................................... 61 
18.4  MULTIPLICITY CONSIDERATIONS  ............................................................................................. 61 
18.5  MISSING DATA .......................................................................................................................... 61 
18.6  POOLING STRATEGY FOR SURGICAL SITES ............................................................................... 61 
18.7  DETERMINATION OF SAMPLE SIZE ............................................................................................ 61 
18.8  DEVIATIONS FROM THE PROTOCOL ANALYSIS PLAN ............................................................... 62 
19.0  ADMINISTRATION OF TH E STUDY ...................................................................... 63 
19.1  REGULATORY CONSIDERATIONS  .............................................................................................. 63 
19.2  INDEPENDENT ETHICS COMMITTEE (EC)/I NSTITUTIONAL REVIEW BOARD (IRB)  .................. 63 
19.3  PATIENT INFORMATION AND INFORMED CONSENT  .................................................................. 63 
19.4  ADHERENCE TO THE PROTOCOL  ............................................................................................... 64 
19.5  PROTOCOL MODIFICATIONS  ..................................................................................................... 64 
19.6  DATA COLLECTION  ................................................................................................................... 64 
19.7  COMPUTERIZED SYSTEMS USED FOR SOURCE DATA ............................................................... 65 
19.8  MAINTAINING RECORDS  ........................................................................................................... 67 
19.9  MONITORING , AUDITING , INSPECTING  ..................................................................................... 67 
19.10  CONFIDENTIALITY  .................................................................................................................... 67 
19.11  PUBLICATION POLICY  ............................................................................................................... 68 
20.0  APPENDIX A: JUSTIFICATION FOR STUDY ENDP OINTS  ............................... 69 
20.1  JUSTIFICATION FOR USE  OF THE FUGL-MEYER MOTOR SCALE AS PRIMARY ENDP OINT  .......... 69 
20.2  RATIONALE FOR NARROW DOMAIN OUTCOME MEASURES IN CHRONIC STROKE PATIENTS 
WITH MOTOR DEFICIT  ............................................................................................................................. 70 
20.3  JUSTIFICATION FOR USE  OF THE ACTION RESEARCH ARM TEST (ARAT)  AS A SECONDARY 
ENDPOINT ................................................................................................................................................. 70 
20.4  JUSTIFICATION FOR USE  OF GAIT VELOCITY AS A SECONDA RY ENDPOINT  .............................. 71 
20.5  JUSTIFICATION FOR USE  OF NEURO QOL  AS A SECONDARY ENDPOINT  .................................... 71 
20.6  JUSTIFICATION FOR CHO ICE OF NEURO QOL  DOMAINS  ............................................................ 72 
21.0  APPENDIX B: WHO STANDARD TOXICITY CRITERIA  ................................... 76 
22.0  APPENDIX C: ANTICOAG ULANT GUIDELINES  ................................................ 84 
23.0  REFERENCES  .............................................................................................................. 85 
 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 5 of 86 LIST OF TABLES  
Table 1:  Summary of SAEs from SB -STR01 Study ............................................................................ 19 
Table 2:  Dose, Volum e and Cell Concentration  .................................................................................. 21 
Table 3:  Schedule of Assessments  ......................................................................................................... 31 
Table 4:  Relationship of Adverse Event to the Administration of the Study Product or Surgery  . 56 
Table 5 : Computerized Systems Used for Source Data  ...................................................................... 66 
Table 6:  WHO (World Health Organization) Toxicity Criteria by Grade  ....................................... 77 
 
LIST OF FIGURES  
Figure  1: ESS ........................................................................................................................................ 18 
Figure  2: NIHSS  ................................................................................................................................... 18 
Figure  3: Fugl -Meyer  ........................................................................................................................... 19 
Figure  4: Study Schematic  .................................................................................................................. 28 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 6 of 86 1.0 PROTOCOL SYNOPSIS  
Protocol #:  SB-STR02  
Title:  A Double -Blind, Controlled Phase  2B Study of the Safety and Efficacy of 
Modified Stem Cells (SB623) in Patients with Chronic Motor Deficit from 
Ischemic Stroke  
Study Objectives:  Primary : 
To evaluate the clinical efficacy of intracranial administration of SB623 cells  
Secondary : 
To evaluat e the effect of intracranial administration of SB623 cells on disability 
parameters  
To evaluate the safety and tolerability of intracranial administration of SB623 
cells 
Background and Rationale  SB623 cells are adult bone -marrow -derived stem cells that have been transiently 
transfected with a plasmid construct encoding the intracellular domain of human 
Notch -1.  SB623 cells secrete factors that protect neurons in models of ischemic 
insult.  In a rat occlusion model of stroke to the middle cerebral artery  region, 
implantation of SB623 into and around the area of the infarct resulted in 
improvement of neurological behavior.  
The safety of implanted SB623 cells was evaluated in a 6 -month primate study 
and in 2 nude rat studies (4 mos. and 12 mos.).  The prima tes were 
immunosuppressed with cyclosporine and the nude rats further 
immunosuppressed with an anti -NK cell antibody.  There were no SB623- related 
clinical, laboratory, or histological abnormalities found. 
The stereotactic surgical delivery of cells to patients with stroke has been shown 
to have an acceptable safety profile in two prior clinical studies with another 
product.  In addition, a retrospective study of over 2,650 patients undergoing 
stereotactic surgery during a 28 -year period at one major cli nic has shown a high 
degree of safety with the procedure.  
A 2 year Phase  1/2a dose escalation study ([STUDY_ID_REMOVED])  of SB623 
stereotactically implanted into the brains of patients with chronic motor deficits 
due to ischemic stroke has been completed.  Result s of a six -month interim s tudy 
report of this study have shown statistically -significant improvements in motor 
function in each of three scales: the European Stroke Scale (ESS), the National Institute of Health Stroke Scale (NIHSS) and the Fugl -Meyer scale.  The study  
showed no serious adverse events attributed to SB623, and only minor adverse 
events mostly grade 1 or 2 (with one grade  3) that were unrelated, unlikely 
related, or possibly related to SB623. No dose -limiting toxicities were observed.  
Based on  the Phase 1/2a  study, SB -STR01, no safety concerns with SB623 were 
seen, but efficacy was suggested.  Therefore, a double -blind, controlled Phase  2b 
study is justified using patients who are not as disabled ( modified Rankin Score 
[mRS  2-4]).  The primary efficacy endpoint will be the Fugl -Meyer Motor Score  
(FMMS) , with the following scales as secondary endpoints:  
• Modified Rankin Scale  
• Action Research Arm Test  
• Gait Velocity  
• NeuroQOL (Upper Extremity Function and  Lower Extremity 
Function)  
• Global Rating of Pe rceived Change:  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 7 of 86 o By Subject (may be completed by Caregiver)  
o By Clinician . 
Study Design  This is a double -blind, sham -surgery controlled study of stereotactic, intracranial 
injection of SB623 cells in patients with fixed motor deficits from ischemic 
stroke.  The study will be conducted at approximately 65 sites in the United 
States.  
Two cohort s, Group 1 (2.5 and 5 million SB623 cells combined) and Group 2 
(sham placebo), will be included in this study.  Subjects who are randomized into 
this study will receive either  approximately  2.5 million SB623 cells, 
approximately  5 million SB623 cells , or sham surgery at a 1:1:1 randomization 
ratio.   Randomization will be performed via an interactive w eb/voice response 
system (IXRS), stratified by Screening mRS score (recorded in the IXRS at the 
clinical site) . 
 
 
Note: Group  1 (Implant) will receive either  approximately  2.5 million SB623 cells or  
approximately  5 million SB623 cells . 
Abbreviation: M  = million.  
The surgical procedure is a modification of one used earlier with another cell 
product (Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplant ation for 
Patients with Subcortical Motor Stroke: A Phase 2 Randomized Trial. J Neurosurg. 2005; 103:38- 45), which has been shown to have a high degree of 
safety in a retrospective study of over 2,600 patients undergoing stereotactic 
surgery over the course of 28 years at one major clinic (Lunsford LD, Niranjan  A, 
Khan  AA, Kondziolka D. Establishing a Benschmark for Complications Using 
Frame -Based Stereotactic Surgery. Sterotact Funct Neurosurg. 2008; 86:278-
287).  
This procedure was also used in the ongoing clinical trial SB -STR01.  On the 
morning of surgery, either a head CT scan overlaid on the Baseline MRI or a head 
MRI scan alone is to be performed for stereotactic targeting.  The MRI scans are 
to use insulated posts, an RIF transmitter head, and at least 1.5 tesla.  Implant sites 
are to be determined in the subcortical peri -infarct tissue to surround the infarct. 
Three needle tracks are to be determined with trajectories to surround the infarct, 
so that cell deposit targets are spaced 5 -6 mm apart. Either frameless or frame 
stereotaxy procedures may be used.  
Group 1  
One burr -hole craniostomy (1- 1.5 cm) is to be fashioned under local anesthesia 
and sedation.  The aim of the sedation is two- fold: to minimize subject discomfort 
and to prevent  any subject recall or awareness of the procedure to preserve subject 

SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 8 of 86 blinding.  The dura is to be opened and a stabilizing cannula (size dependent on 
the use of a frame or frameless procedure) containing a removable solid stylet is 
to be inserted to a poi nt just proximal to the penumbra of the stroke area.  The 
solid stylet is then to be removed, followed by insertion into the stabilizing cannula of an implantation cannula (previously qualified for product stability and 
delivery and provided by the Sponsor , as needed) down to the deepest target point 
for the first implantation.  A safe trajectory to enter a 100  µL of cell suspension is 
defined. A volume of 125  µL of cells is backloaded into a 100 µL syringe, 25 µL 
of these cells are injected to clear the im plant cannula, thus the final volume in the 
syringe for implant is 100 µ L. Detailed information will be provided separately 
from this protocol in a n Investigational Product  Manual . Five 20 -µL volumes of 
cells are to be injected slowly (approximately 10  µL/min.) into 5 implantation 
sites, slowly withdrawing the stabilizing needle probe to produce equally spaced implants (intervals of 5 -6 mm) within the peri- infarct region extending from 
inferior to the infarct to superior to the infarct.  The target locat ions will be 
selected by the site neurosurgeon to be closest to the motor pathway based on the 
patient’s own neuroanatomy.  This procedure is to be repeated with 2 other needle 
tracks with different trajectories, inserted through the same burr -hole cranios tomy.  
Group 2  
Group 2 will receive sham surgery (sedation, stereotactic planning procedure, 
partial -thickness skull outer table burr hole, scalp suture, but no penetration of 
inner table or dura mater) .  This will be done under sedation and local anestheti c.  
Again the purpose of the sedation is two -fold: to minimize subject discomfort and 
to prevent any subject recall or awareness of the procedure to preserve subject 
blinding.  The sham surgery procedure will be scripted to mimic as closely as 
possible the  procedure undertaken by Group 1.  Subjects in Group 2 will remain 
in the operating room for the same duration as Group 1.  
Post-Surgical  
After completion of the procedure, both groups will receive a CT scan and be admitted to a neurosurgical patient ward for 24  hour observation.  The patient will 
be discharged on the first post -
operative day unless complications require a longer 
stay.  An MRI is to be done on the first post -operative day prior to discharge (Day 
2) to insure there are no significant bleedin g risks.  
The neurological assessment team evaluating Fugl -Meyer and other efficacy 
endpoints will be blinded, with the subjects also blinded.  The surgical team will 
remain unblinded, any communication between the surgical and neurological 
team (including the investigator) will be blinded regarding treatment  assignment . 
Safety will be monitored throughout the study.  In addition an external Data 
Safety Monitoring Board will be utilized to review safety data , including clinical 
symptoms, laboratory findings, and MRI brain imaging.  Two or more serious 
adverse events potentially attributed to SB623 as assessed by the Investigator will 
trigger a review by the DSMB before continuing enrollment.  In addition, the 
DSMB will review the study for safety at 25% , 50% , and 75%  enrollment.  The 
DSMB shall be the fina l arbitrator for attributions.  
Efficacy will be determined based on changes in the clinical measures of stroke 
through standardized assessments (Fugl -Meyer Mo tor Scale (FMMS), Modified 
Rankin Scale (mRS), Action Research Arm Test (ARAT), Gait Velocity and two 
sub-domains of the NeuroQOL scale).  MRI of the brain will be performed at 
scheduled time points (pre-  and post -contrast T1 weighted, dual echo, and F luid 
Attenuated I nversion R ecovery [ FLAIR ] sequences). MRIs will be analyzed by a 
central reader post -surgery and blinded reports will be sent back to the assessment 
site staff (excluding the assessment site efficacy assessor) without any 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 9 of 86 accompanying images. E xploratory imaging (e.g. diffusion tensor imaging [DTI] 
and dynamic susceptibility contrast [ DSC ] MRI for perfusion imaging) will also 
be performed  at capable sites.  Primary and secondary efficacy assessments will 
be completed solely by blinded study pers onnel that do not have access to patient 
study safety information (this include s adverse events, concomitant medications, 
progress notes, and MRI reports ). 
Stopping Rules:  
If the DSMB determines that continuation of enrollment in the trial provides an 
unreasonable risk to the patients, it may recommend study termination.  All SAEs, 
regardless of attribution shall be reviewed by the DSMB.  
In addition, adverse events attributable to the surgical procedure, such as intracranial infection, intracranial blee ding, or seizures, shall be subject to review 
by the DSMB.  
The DSMB shall be the final arbitrator for attributions.  
Patient Population  Adult patients with chronic motor deficits secondary to ischemic stroke between 
6 months and 90 months  (7.5 years) post stroke.  The interval of 6 months to 
90 months ( 7.5 years ) for this patient population is based on a number of studies 
that have shown that over 90% of ischemic stroke patients are stable by 90 days 
post-stroke.  A Phase  1/2a study (SB -STR01) was conducted  to investigate safety 
and efficacy of intracranial administration of SB623 cells in chronic stroke 
patients with motor deficit . 
No. of Patients  Approximately 156 subjects 
No. of Study Sites  Approximately  65 sites  
Inclusion Criteria  1. Age 18 -75 years, inclusive  
2. Documented history of completed ischemic stroke in subcortical region of 
MCA or lenticulostriate artery with or without cortical involvement, with 
correlated findings by MRI  
3. Between 6 months and 90 months  (7.5 years) post -stroke, and having a 
chronic motor neurological deficit  
4. Neurological motor deficit substantially due to incident stroke  (ie, the stroke 
that qualified the patient for the study)  
5. Modified Rankin Score of 2- 4 
6. Require Motricity Index 30- 75 (UE Scale) or  27-74 (LE  Scale)  
7. Able to undergo all planned neurological assessments  
8. Able and willing to undergo magnetic resonance imaging (MRI)  with contrast 
and computed tomography (CT)  
9. Agree that use of antiplatelet, anti -coagulant, or non- steroidal anti -
inflammatory drugs be in accordance w ith the Anticoagulant Gu idelines 
described in Appendix C . 
10. Subjects must have had physical therapy prior to entry and be willing to continue to the extent possible  
11. Must be willing to discontinue herbal or non- traditional medicines for 1  week 
before and 1  week after the surgical procedure  
12. Ability of patient to understand and sign an Informed Consen t 
Exclusion Criteria  1. History or presence of any other major neurological disease other than stroke  
2. Cerebral infarct size > 150 cm3 measured by MRI  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 10 of 86 3. Primary intracerebral hemorrhage  
4. Myocardial infarction within prior 6 mos.  
5. Malignancy unless in remission > 5 yrs. 
6. Clinically significant finding on MRI of brain not related to stroke  
7. Any seizures in the 3 months  prior to Screening  
8. More than 5 degrees of contractur e at shoulder, elbow, wrist, fingers, hip, 
knee and ankle  
9. Other neurologic, neuromuscular or orthopedic disease that limits motor 
function  
10. Uncontrolled systemic illness, including, but not limited to: hypertension; 
diabetes; renal, hepatic, or cardiac fai lure 
11. Positive findings on tests for occult malignancy, unless a non- malignant 
etiology is confirmed  
12. Uncontrolled major psychiatric illness, including depression symptoms (CESD -R Scale of ≥16 is exclusionary ) 
13. Total bilirubin >1.9 mg/dL  at Screening  
14. Serum creatinine >1.5 mg/dL  at Screening  
15. Hemoglobin <10.0 g/dL at Screening  
16. Absolute neutrophil count <2000 /mm3 at Screening  
17. Absolute l ymphocytes <800 /mm3 at Screening  
18. Platelet count <100,000 /mm3 at Screening  
19. Liver disease supported by AST (SGOT) or ALT (SGPT ) ≥2.5 x upper limit 
of normal  at Screening  
20. Serum calcium >11.5 mg/dL  at Screening  
21. International Normalized Ratio of Prothrombin Time (INR)  >1.2 at 
Screening , if the patient  does not take anticoagulants; f or patients on 
anticoagulants, INR must be confirmed to be ≤1.2 prior to surgery  
22. Presence of craniectomy (without bone flap replacement) or other 
contraindication to stereotactic surgery  
23. Participation in any other investigational trial within 4  weeks of i nitial 
screening and within 7 weeks of Baseline visit  
24. Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other 
interventional treatments for spasticity (except bracing and splinting) 
16 weeks prior to the Baseline visit  
25. Substance use disorder (per DSM -V criteria, including drug or alcohol)  
26. Contraindications to head MRI (with contrast) or CT  
27. Pregnant or lactating  
28. Female patients of childbearing potential unwilling to use an adequate birth control method during the 12 months of the study  
29. Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and conduct of the study  
30. Any prior SB623 cell implantation and/or any prior stem cell treatment for stroke or other reason regardless of mode of administration  
31. Subject is taking any prohibited medications (see Section 12.0)  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 11 of 86 Dosage, Mode of 
Administration, 
and Treatment 
Duration  The investigational product, SB623 cells, are sterile cell suspension in unit 
volume of 1 mL, containing ≥8 X  106 cells/mL, cryopreserved in CryoStore™ 
freezing media in a 2  mL vial.  
Cells to be administered stereotactically only once through one burr -hole 
craniostomy within and adjacent to the infarct using 3  needle tracks and 5  cell 
deposits per track at vary ing depths (20 µL each):  
• Approximately 2.5 X  106 SB623 Cells (8.5 X 106 cells/mL)  
• Approximately 5.0 X  106 SB623 Cells (17 X 106 cells/mL)  
Details for preparation of the cell suspension for administration and for loading the syringe in the Operation Room will be provided by the Sponsor to the clinical 
site unblinded personnel who will performed the cell target concentration 
preparation, labeling, administration and accountability of investigational product. 
 
Detailed information will be provided separately  from this protocol in a Pharmacy 
Manual.  Clinical sites will be provided with the necessary materials for 
reconstitution of the cells and will be trained by the Sponsor.  
The cryopreserved cells will be thawed, washed, centrifuged, and re -suspended in 
Plasma-Lyte A to achieve target concentrations of approximately 2.5  X 106 cells/ 
0.3 mL and approximately 5 X 106 cells/ 0.3  mL, respectively.  The formulated 
dose for injection is packaged individually in 1.0 mL conical Nalgene ™ vi als 
with a Teflon seal clos ure. 
Prior to administration, a gram stain and a test for endotoxin will be done and a 
sterility test initiated on the last cell wash to insure continued sterility for release 
of target concentrations.  The formulated dose for injection must be administere d 
to the patient within 3 hours  post release testing.  
If the endotoxin level is > 5 EU/mL or the gram stain is positive, implantation will 
not occur.  If the sterility test is positive, an investigation will be conducted to determine the source of the contamination.  In addition, identification of the 
pathogen and sensitivity will be done and the patient treated with an appropriate 
antibiotic.  In this event, the patient will be followed closely for adverse events 
associated with a possible infection and response to antimicrobial therapy, 
including frequent clinic visits until any infection is cleared . 
The cryovials containing the frozen cell suspensions are shipped in a dry nitrogen 
shipper and should be stored in the vapor phase (≤  -150 C) within the shipping 
container provided by the Sponsor until transferred at the site to a GMP -compliant 
liquid nitrogen container.  At the clinical site, the investigational product should 
be stored in the vapor phase (≤  -150 C) within the liquid nitrogen container.  
Duration of 
Patient Study 
Participation  Twelve months post -randomization (except if there is an unresolved adverse event 
of at least Grade  2 and at least possibly related to the therapy, in which case the 
patient will be followed until resolved or reduced to Grade  1). 
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 12 of 86 Efficacy 
Parameters Primary Efficacy Endpoint:  
• Proportion of subjects whose Fugl -Meyer Motor scale (FMMS) improve 
by ≥10 points at Month 6 from Baseline  
Secondary Efficacy Endpoints:  
• Proportion of subjects whose Modified Rankin Scale (mRS) improve 
by ≥1 point at Month 6 from Baseline  
• Proportion of subjects whose Action Research Arm Test (ARAT)  
improve by ≥6 points at Month 6 from Baseline  
• Proportion of subjects whose Gait Velocity on standard 10 m walk  
improve at least o ne functional level [eg, from < 0.4 m/s to 0.4- 0.8 m/s or 
from 0.4 -  0.8 m/s to > 0.8 m/s]) at Month  6 from Baseline  
• Mean change in T scores at Month 6 of NeuroQOL sub -domains:  
o Upper Extremity Function (Fine motor ADL)  
o Lower Extremity Function (Mobility)  
• Proportion of subjects scoring 7  (much better) or 6 (a little improved) in 
the Global Rating of Perceived Change scores at Month 6 a ssessed by 
subject (may be completed by caregiver) and by clinician  
Safety Parameters  • All adverse events whether or not related to SB623 or surgic al procedure 
using WHO toxicity criteria  
• Adverse changes imaged by head MRI  
• Serious adverse events (SAEs) using WHO toxicity criteria  
• Serum chemistry , hematology, vital signs, physical examinations  
• Changes in serum antibodies to SB623 over time  
Explorator y  • Standard T1-  and T2- weighted MRI  
• Fluid -attenuated Inversion Recovery (FLAIR)  
• Dynamic Susceptibility Contrast (DSC) imaging  
• Diffusion tensor imaging (DTI) with tractography and perfusion imaging 
• Motion of leg on side affected by stroke as measured by leg activity monitor  
SanBio, Inc.   Confidential and Proprietary  
Protocol SB -STR02 05  January 2017  Page 13 of 86 Statistical 
Methods  Sample Size:  
The sample size was estimated based on the primary efficacy endpoint, proportion 
of responders, which is defined as ≥ 10 points on the FMMS, at Month 6 LOCF 
(last observation carried forward).  Based o n the results on the Phase  1/2a study it 
was assumed that the responder rate was 33% for the SB623 treatment group.  
Given high surgical placebo response rates (Meissner et al., 2013) it was assumed that the responder rate in the surgical sham was 11.7% (i.e. 35% of the treatment 
responder rate).  Assuming a 80% power, alpha level of 0.05 (two- tailed test), and 
2:1 (pooled SB623 treatment s:control) ratio of randomization, a sample size of 
138 (92 subjects in treatment group and 46 subjects in control group) is required 
to detect this 21.3% difference in the proportion of responders.  Based on a 
10% upward adjustment to compensate for dropout patients, a total of 
approximately 156 subjects (104 treatment and 52 control) will be required.  
 
Primary Efficacy Analyses:  
The primary analysis will be a comparison of the proportion of SB623 treated 
subjects ( two SB623 doses  combine d) to sham controls that achieve an 
improvement of at least 10 points on the Fugl -Meyer Motor Scale at 6  months 
from Baseline.  A logistic generalized linear mixed model (GLMM) will be used for the primary analysis.   
 
Secondary Efficacy Analyses  
The responder analysis in mRS  and other disability scales will be assessed 
similarly to the model utilized for the primary analysis.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 14 of 86 2.0 BACKGROUND  
2.1 Medical Need  
Stroke is the third leading cause of death in the United States and a  major cause of prolonged 
neurologic disability in adults, with an annual economic burden of over $62 billion in the United 
States.  Of those who experience an ischemic stroke, approximately one quarter will not survive.  
Of the survivors, more than a thir d will remain functionally dependent due to their physical and 
cognitive limitations.1,2,3,4,5,6,7,8 
Following an ischemic stroke the acute period is generally defined from hours to several days following the event.  Longitudinal studies on rates of improvement after ischemic stroke have shown that 90% of patients with ischemic stroke achieve no further improvement after about 
90 days with current standard of care.
9  This time period was found to be independent of degree 
of initial severity regardless of methods used to assess by most investigators,10,11 while others 
found that severe and very severe cases continued to have slight improvement for 2- 3 weeks 
more using a  different method of assessment.12 
Approximately 70–85% of first strokes are accompanied by hemiplegia.  Six  months  after stroke, 
only 60% of people with hemiparesis who need inpatient rehabilitation have achieved functional independence in simple activities of daily living such as toileting and walking short distances.  
Studies of patients 6 months  after stroke with h emiparesis suggest that only about 1 in 5 patients 
achieve unlimited community ambulation following inpatient rehabilitation.
13 
2.2 Treatment of Ischemic Stroke 
2.2.1 Current Therapies  
For acute ischemic stroke, immediate post- stroke interventions focus on life support through 
respiratory and cardiac control of blood pressure, monitoring oxygen saturation and blood glucose level, prevention of metabolic disturbances, maintenance of organ function, and 
management of elevated intracranial pressure.
14  The only approved t herapies in the U.S. are 
thrombolytic agents, to be given within 3 hrs. of onset of the stroke.  It has been estimated that 
less than 5% of acute ischemic stroke patients receive this therapy, probably due to the stringent 
criteria for thrombolytic interve ntion, the patient arrival beyond the 3- hour window, and lack of 
adequate facilities at many hospitals.15  As the stroke fully develops, and the patient stabilizes, 
some regimen of physical therapy is almost universally applied.  
2.2.2 Time Course for Stable Strok e 
Acute ischemic stroke is generally accepted to be defined as up to several days, if not hours.  
Longitudinal studies on rates of improvement after ischemic stroke have shown that 90% of 
patients with ischemic stroke achieve no further improvement after a bout 90 days.16 
2.2.3 Experimental Cellular Therapies  
For the stable stroke patient, no proven therapies exist to reverse the damage and improve overall motor or cognitive function.  As reviewed recently, a variety of cellular therapies have been examined.
17,18,19  Clinical trials with these agents have so far been limited, with only three trials 
conducted and reported to date, with only two having used human cells.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 15 of 86 Fetal cells from the porcine lateral ganglionic eminence which had been shown to improve 
deficits in a n animal model of Huntington’s disease,20,21 and in an animal model of middle -
cerebral artery occlusion22 were studied in a Phase 1 clinical trial.  Five patients with chronic, 
stable, moderate -sized basal ganglia infarcts received intrastriatal implantation of the cells.  One 
of the patients developed a cortical vein occlusion, and the study was terminated by the F ood and 
Drug A dministration .  Attribution of the adverse event has not been clarified.  None of the 
patients showed improvement on the Modified Rankin Scale.19 
Cultured human neurons derived from an embryonal carcinoma cell line that was isolated from a 
teratocarcinoma (LBS -Neurons) which had been shown to improve deficits in an animal model 
of middle -cerebral artery occlusion23 were studied in an open- label Phase 1 clinical trial.24, 
Initially, 4 patients with stable stroke received stereotactic implants 2 million cells in one needle track into the area of infarction, divided into 3 implants with 20 µL per implant.  Subsequently, 
8 additional patients were randomized to receive either single -pass (2 million cells in 3  implants) 
or 3-pass (6 million cells in 9 implants) in jections into the area of infarction.  All patients also 
received cyclosporine  A orally.  The outcomes were that the procedures and injections were well 
tolerated with a mean improvement in all patients by the European Stroke Score (ESS) that was 
statistic ally significant, and with an improvement in FDG -PET scans in half of the patients at 
6 months . 
Based on the encouraging results from that Phase 1 study, an open- label, observer -blinded 
Phase 2 study was conducted with LBS -Neurons in 18 patients who were r andomized between 
surgery with 5 or 10 million cells implanted (25 implantation sites) plus rehabilitation (14 patients), or rehabilitation alone (4 patients), with all surgical patients also receiving 
cyclosporine  A orally.
25  The patient mix was approxima tely an equal number with ischemic or 
hemorrhagic stroke.  The outcomes were that both the procedure and the cell implants were again 
well tolerated.  There was no statistically -significant improvement in the ESS between groups, 
although some improvements were found when patients were analyzed as their own controls.  
Some cognitive improvements were also noted.  Finally, there were statistically -significant 
improvements in some of the Fugl -Meyer assessments, but not on overall motor function. 
2.2.4 Stereotactic S urgery  
In addition to the two studies referred to above with LBS Neurons, a retrospective study of over 2,650 patients who received stereotactic surgery over a 28 -year period at one major clinic found 
an incidence of surgery -related complications to be <1% , establishing the high degree of safety 
for this procedure.  Complications reported included a need for a craniotomy for hematoma 
evacuation (0.36%), perioperative seizures (0.36%), burr hole infections (0.08%), and death 
(0.08%).
26  Further, a Phase 1/ 2a study with SB623 has been completed with all subjects 
followed through 24 months post -infarct .  During this study there were serious adverse events 
attributed to the surgery, including subdural hematoma, hygroma, se izure disorder, and 
pneumonia . 
2.3 Properties  of SB623 
2.3.1 Summary of SB623 Cells Properties  
SB623 cells are human bone marrow -derived cells and are being developed as an allogeneic cell 
therapy for chronic, stable stroke and other neurodegenerative conditions.  SB623 cells are generated under cGMP condi tions by the transient transfection of bone marrow stromal cells 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 16 of 86 (MASC) with a plasmid encoding the human Notch- 1 intracellular domain.27  This transfection is 
considered transient because the plasmid rapidly disappears with further expansion/passaging of 
the cells.  Thus, the gene and its products which were initially detected at very low levels are not 
expected to be present at all after a short time post -implantation.  
Unlike the MASC cells used to produce SB623 cells, the product has limited potential to differentiate into bone or adipose cells.  
2.3.2 Summary of Notch- 1 Gene Properties  
Notch -1 is involved in the regulation of the development process in many species, including 
humans.  Notch is a heterodimeric transmembrane receptor.  Its natural ligands (Serrate, Jagged, Delta) are also integral membrane proteins, revealing a cell -cell or juxtacrine role for Notch.  
Once stimulated by a ligand, Notch is proteolytically cleaved releasing the Notch IntraCellular 
Domain (NICD) from the plasma membrane.  Once released, the NICD migrates to the nucleus 
where it plays the role of an activating transcription factor for a number of genes.  
2.3.3 Preclinical Pharmacology Studies  
SB623 has been evaluated in a rat model of ischemic stroke in three studies.  Overall, SB623 
showed statistically -significant benefit on several neurological and motor outcomes compared to 
vehicle control.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 17 of 86 3.0 Overall Experience with Investigational Product  
This section includes a brief summary of preclinical data available on SB623.  More detailed 
information can be found in the Investigator’s Drug Brochure for SB623 cells.  
3.1 Study Agent  
SB623 cells are bone -marrow -derived stromal cells that have been transiently transfected with 
the intercellular domain of the human Notch- 1 gene. 
3.2 Preclinical Pharmacology  
3.2.1 In Vitro  
The in vitro  characterization of SB623 cells has included 8 basic areas: fate of SB623 cells, 
protection of primary neurons from Oxygen Glucose Deprivation, the secretion of neurotrophic factors, Notch -1 signal transduction, epigenetic changes, osteo-  and adipogenesis , and 
anti-inflammatory properties of SB623.  
Several studies evaluating the pharmacology and toxicology of SB623 cells ( cell dosage, 
pharmacokinetics, formulation, efficacy, safety, biodistribution, tumorigenicity and use with cyclosporine ) have been conducted.  See the Investigator’s Drug Brochure for details on these 
studies. 
3.3 Clinical Experience 
A 2-year Phase 1/2a study (SB-STR01 - [STUDY_ID_REMOVED])  to investigate  the safety and efficacy 
of int racranial administr ation of S B623 cells in chronic st roke patients with motor def icit has 
been completed .  This was  an open- label study of  18 chronic ischemic stroke patients who were 
shown to be stable in the 3 weeks prior to enrollment.  The dose levels used were in a standard 
dose escalation paradi gm: approximately 2.5M, 5.0M, and 10.0M cells administered once into 
the peri -infarct region of the brain.  Four stroke measurement scales were used: NIHSS, ESS, 
F-M, and m RS.  A ll of these scales , except m RS, showed a statistically -significant av erage 
improvement over Baseline at 6  months  and other time points .  For example, t he average change 
from Baseline in the F -M scale was found to be 22 at six  months  (see Figures 1 -3 below) .  The 
F-M scale is considered sensitive to improvements in motor function in stroke patients.  Page , et 
al. (2012) evaluated the clinically important difference in the Upper Extremity F-M (UE F -M) to 
range from 4.25 to 7.25 points based on a study of 146 patients with chronic stroke.
28 The 
average change from Baseline in the UE F -M in SB -STR01 was 5.94 and therefore in the range 
of clinically important difference as defined by Page et al.  Page, et al.  also discusses a clinically 
important difference in the context of 10% improvement over the scale range.  The average 
improvement score on the F -M scale in SB -STR01  was 22.19 points  which is a  10% 
improvement over the 226 point F -M scale range and a 16% increase over baseline.  T herefore, 
clinically relevant improvements have been demonstrated by 6  months  post treatment.  
The mRS  scale did not show statistical or clinically meaningful change from baseline.  Two 
subjects had an improvement of  1, and 1 subject had a 1 point worsening.  Others were 
unchanged during the course of the study.  
Both the NIHSS and the ESS were originally d eveloped as predictors of acute stroke 
outcome.29,30  They were both also used in the Phase 1/2a study due to their common use in acute 
stroke in the U.S. and Europe, respectively.  See figures below . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 18 of 86 Figure  1: ESS 
 
 
Figure  2: NIHSS  
 
 
ESS
Months Post -treatmentChange from Baseline ( +SEM)P=.003P=.02
P=.004Clinical Outcome
NIHSS
Months Post -treatmentChange from Baseline ( +SEM)
P=.004P=.03
P=.0006Clinical Outcome
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 19 of 86 Figure  3: Fugl -Meyer  
 
3.4 Summary of Known and Potential Risks and Benefits  
A Phase 1/2a study (NCT012879 36) in chronic stroke patients with motor deficit has been 
completed .  There was a common theme of headache and local pain post -surgical procedure, but 
these were mild and transient.  There were no ser ious adverse events attributable to SB623.  All 
of the SAEs observed to date (six  months  post implant of the last patient) are summarized in 
Table 1 below.  
Table 1:  Summary of SAEs from SB -STR01 Study  
Subject  Event  Grade  Attribution 
Cells  Attribution Surgery  Reason for SAE  
01-006 Seizure Disorder  4 Unrelated  Possibly 
Related  Hospitalization  
01-007 Subacute Subdural 
Hematoma (with 
Hygroma below)  3 Unrelated  Definitely 
Related  Hospitalization  
01-007 Hygroma  3 Unrelated  Definitely Related  Hospitalization  
01-012 UTI 4 Unrelated  Unrelated  Hospitalization  
02-001 ICA Stenosis  3 Unrelated  Unrelated  Hospitalization  
02-003 Recurrence of Stroke 
Symptoms  1 Unlikely 
Related  Unrelated  Hospitalization  
02-006 Pneumonia  3 Unrelated  Probably Related  Hospitalization  
 
Fugl-Meyer
Months Post -treatmentChange from Baseline ( +SEM)P=.0002P=.0006
P=.000006Clinical Outcome
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 20 of 86 No safety concerns with SB623 have been found.  The Adverse Events attributed to SB623 have 
been Grade 3 or less, with attributions no higher than Possibly Related.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 21 of 86 4.0 DESCRIPTION AND JUST IFICATION OF TREATME NT REGIMEN  
4.1 Dosages  
Cells are to be administered stereotactically through one burr -hole craniostomy using 3 needle 
tracks adjacent to the infarct and 5 cell deposits per track at varying depths, with 20 µL per 
deposit. 
Based on the 6 -mo. follow -up data from SB -STR01, there was no apparent dose response in 
either safety or efficacy measures.  Also, all doses were well tolerated.  The dose of 10.0 million 
cells was associated with higher viscosity, making syringe -loading more difficult.  The refore, the  
two types of dose s chosen for this Phase 2b study  are approximately 2.5 and approximately 
5.0 million  cells .  See Table 2 below.  
Table 2:  Dose, Volume and Cell Concentration  
Total SB623  
Cells/Pt.  Total SB623  
Cells/Deposit  Total SB623 
Cells/Track  Concentration of SB623 Cells per Injection  Total Volume per 
Deposit, per 
Track, and Total  
~2.5 X 106 1.7 X 105 8.5 X 105 8.5 X 106 
cells/mL  20 µL,  100 µL, and 
300 µL  
~5.0 X 106 3.3 X 105 16.5 X 105 17 X 106 cells/mL  20 µL, 100 µL, and 
300 µL  
 
4.2 Justification  
Based on the Phase 1/ 2a study, SB -STR01, no safety concerns with SB623 were seen, but 
efficacy was suggested.  Therefore,  a double -blind, controlled Phase 2b study is justified using 
patients who are not as disabled (mRS 2- 4).  The primary efficacy endpoint will be the Fugl -
Meyer  Motor Score, with the following scales as  secondary endpoint s: 
• Modified Rankin Scale  
• Action Research Arm Test  
• Gait Velocity  
• NeuroQOL (Upper Extremity Function and Lower Extremity Function)  
• Global Rating  of Perceived Change:  
o By Subject ( The subject  global rating of perceived change should be completed 
by the subject . In the event the subject  is not able to complete the questionnaire, 
the c aregiver will be allowed to ask the questions of the subject  and complete the 
questionnaire using the subject’s  answer(s) ) 
o By Clinician  
Rationales for selecting study endpoints are provided in Appendix A. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 22 of 86 5.0 STUDY PA RAMETERS AND OBJECTI VES  
The overall objective of the study is to evaluate the safety and efficacy of SB623 cells 
stereotactically implanted in the brains of patients with stable ischemic stroke.  
5.1 Parameters  
5.1.1 Primary Efficacy  Endpoint : 
• Proportion of subjects whose Fugl -Meyer Motor scale (FMMS) improve by 
≥10 points at Month 6 from Baseline  
5.1.2 Secondary Efficacy Endpoints:  
• Proportion of subjects whose Modified Rankin Scale (mRS) improve by ≥1 point at 
Month 6 from Baseline  
• Proportion of subjects whose Action Res earch Arm Test (ARAT) improve by 
≥6 points at Month 6 from Baseline  
• Proportion of subjects whose Gait Velocity on standard 10 m walk improve at least one functional level [eg, from < 0.4 m/s to 0.4- 0.8 m/s or from 0.4 -  0.8 m/s to 
>0.8 m/s]) at Month 6 from Baseline  
• Mean change in T scores at Month  6 of NeuroQOL sub- domains  
o Upper Extremity Function (Fine motor ADL)  
o Lower Extremity Function (Mobility)  
• Proportion of subjects scoring 7 (much better) or 6  (a little improved) in the Global 
Rating of Perceived Change scores at Month 6 a ssessed by  subject (may be 
completed by caregiver) and by clinician  
5.1.3 Safety  Endpoints  
• All adverse events whether or not related to SB623 or surgical procedure using WHO toxicity criteria  
• Adverse changes imaged by head MRI  
• Serious adverse events (SAEs) using WHO toxicity criteria  
• Serum chemistry hematology, vital signs, physical examinations  
• Changes in serum antibodies to SB623 over time  
5.1.4 Exploratory  Endpoints  
• Standard T1-  and T2 -weighted M RI 
• Fluid -attenuated Inversion Recovery (FLAIR)  
• Dynamic Susceptibility Contrast (DSC) imaging  
• Diffusion tensor imaging (DTI) with tractography  and perfusion imaging 
• Motion of leg on side affected by stroke as measured by leg activity monitor  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 23 of 86 5.2 Objectives  
5.2.1 Prim ary Objective  
• To evaluate the clinical efficacy of intracranial administration of SB623 cells  
5.2.2 Secondary Objectives  
• To evaluate the effect of intracranial administration of SB623 cells on disability 
parameters  
• To evaluate the safety and tolerability of intr acranial administration of SB623  cells  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 24 of 86 6.0 SURGICAL AND I MPLANTATION P ROCEDURES  
The surgical procedure is a modification of one used earlier with another cell product ,25 and 
which has been shown to have a high degree of safety in a retrospective study of over 
2,600 patients undergoing stereotactic surgery over the course of 28 years at one major clinic.26  
This procedure was also used in the ongoing clinical trial SB -STR01.  Two cohorts, Group 1 (2.5 
and 5 million SB623 cells combined) and Group 2  (sha m placebo) , will be included in this study.  
Subjects who are randomized into this study  will receive either approximately 2.5 million SB623 
cells,  approximately 5 million SB623 cells  or sham surgery at  a 1:1:1 randomization ratio .  On 
the morning of surgery, either a head CT scan overlaid on the Baseline MRI or a head MRI scan alone is to be performed for stereotactic targeting.  The MRI scans are to use insulated posts , an 
RIF transmitter head, and at least 1.5 tesla.  Implant sites are to be determined in the subcortical 
peri-infarct tissue to sur round the infarct .  Three needle tracks are to be determined with 
trajectories to surround the infarct, so that cell deposit targets are spaced 5 -6 mm apart .  Either 
frameless or frame stereotaxy procedures may be used. 
Group 1  
One burr -hole craniostomy (1- 1.5 cm) is to be fashioned under local anesthesia and sedation.  
The aim of the sedation is two -fold: to minimize subject discomfort and to prevent any subject 
recall or awareness of the procedure to preser ve subject blinding.  The dura is to be opened and a 
stabilizing cannula (size dependent on the use of a frame or frameless procedure) containing a 
removable solid stylet is to be inserted to a point just proximal to the penumbra of the stroke area.  The s olid stylet is then to be removed, followed by insertion into the stabilizing cannula of 
an implantation cannula ( previously qualified for product stability and delivery and provided by 
the Sponsor, as needed) down to the deepest target point for the first  implantation.  A safe 
trajectory to enter a 100  µL of cell suspension is defined. A volume of 125 µ L of cells is 
backloaded  into a 100 µ L syringe, 25 µ L of these cells are injected to clear the implant cannula, 
thus the final volume in the syringe for implant is 100 µ L. Detailed information will be provided 
separately from this protocol in a n Investigational Product  Manual .  Five  20-µL volumes of cells 
are to be injected slowly (approximately 10 µL/min.) into 5 implantation sites, slowly withdrawing the stabilizing needle probe to produce  equally spaced implants (intervals of 
5-6 mm) within the peri -infarct region extending from inferior to the infarct to superior to the 
infarct.   The target locations will be selected by the site neurosurgeon to be closest to the motor 
pathway based on the patient’s own neuroanatomy.  This procedure is to be repeated with 2 other needle tracks with different trajectories, inserted through the same burr -hole craniostomy.  
Group 2  
Group 2 will receive sham surgery (sedation, stereotactic planning procedure, partial -thickness 
skull outer table burr hole, scalp suture, but no penetration of inner table or dura mater).  This 
will be done under sedation and local anesthetic.  Again the purpose of the sedation is two- fold: 
to minimize subject discomfort and to prevent any subject recall or awareness of the procedure to 
preserve subject blinding.  The sham surgery procedure will be scripted to mimic as closely as 
possible the procedure under taken by Group 1.  Subjects in Group 2 will remain in the operating 
room for the same duration as Group 1.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 25 of 86 Post-Surgical  
After completion of the procedure, both groups  will receive a CT scan and be admitted to a 
neurosurgical patient ward for 24 hour observation.  The patient will be discharged on the first 
post-operative day  unless complications require a longer stay .  An MRI is to be done on the first 
post-operative day prior to discharge (ie, Day 2) to insure there are no significant bleeding risks . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 26 of 86 7.0 PATIENT S ELECTION  
7.1 Inclusion Criteria  
1. Age 18- 75 years, inclusive  
2. Documented history of completed ischemic stroke in subcortical region of MCA or 
lenticulostriate artery with or without cortical involvement, with correlated findings by MRI  
3. Between 6 months and 90  months  (7.5 years ) post -stroke, and having a chronic motor 
neurological deficit  
4. Neurological motor deficit substantially due to incident stroke (i.e. the stroke that qualified the patient for the study)  
5. Modified Rankin Score of 2- 4 
6. Require Motricity  Index 30- 75 (UE Scale) or  27-74 (LE Scale)  
7. Able to undergo all planned neurological assessments  
8. Able and willing to undergo magnetic resonance imaging (MRI)  with contrast and 
computed tomography (CT)  
9. Agree that use of antiplatelet, anti -coagulant, or non- steroidal anti- inflammatory drugs be 
in accordance with the Anticoagulant Guidelines described in Appendix C  
10. Subjects must have had physical therapy prior to entry (and be willing to continue to the extent possible)  
11. Must be willing to discontinue herbal or  non- traditional medicines for 1 week before and 
1 week after the surgical procedure.  
12. Ability of patient to understand and sign an Informed Consent  
7.2 Exclusion Criteria  
1. History or presence of any other major neurological disease other than stroke 
2. Cerebral infarct size >150 cm
3 measured by MRI  
3. Primary intracerebral hemorrhage  
4. Myocardial infarction within prior 6 mos. 
5. Malignancy unless in remission > 5 yrs. 
6. Clinically significant finding on MRI of brain not related to stroke  
7. Any seizures in the 3  months  prior to Screening  
8. More than 5 degrees of contracture at shoulder, elbow, wrist, fingers, hip, knee and ankle  
9. Other neurologic, neuromuscular or orthopedic disease that limits motor function  
10. Uncontrolled systemic illness, including, but not limited to: hyperten sion; diabetes; 
renal, hepatic, or cardiac failure  
11. Positive findings on tests for occult malignancy, unless a non- malignant etiology is 
confirmed  
12. Uncontrolled major psychiatric illness, including depression symptoms (CESD -R Scale 
of ≥16 is exclusionary ) 
13. Total bilirubin >1.9 mg/dL  at Screening  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 27 of 86 14. Serum creatinine >1.5  mg/dL  at Screening  
15. Hemoglobin <10.0 g/dL at Screening  
16. Absolute neutrophil count <2000 /mm3 at Screening  
17. Absolute l ymphocytes <800 /mm3 at Screening  
18. Platelet count <100,000 /mm3 at Screening  
19. Liver disease supported by AST (SGOT) or ALT (SGPT) ≥2.5 x upper limit of normal  
at Screening  
20. Serum calcium >11.5  mg/dL  at Screening  
21. International Normalized Ratio of Prothrombin Time (INR) >1.2 at Screening , if the 
patient  does not take anticoagulants; f or patients on anticoagulants, INR must be 
confirmed to be ≤ 1.2 prior to surgery  
22. Presence of craniectomy (without bone flap replacement) or other contraindication to 
stereotactic surgery  
23. Participation in any other investigational trial within 4  weeks of i nitial screening and 
within 7  weeks of Baseline visit  
24. Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other 
interventional treatments for spasticity (except bracing and splinting) within 16 weeks of the B aseline visit. 
25. Substance use disorder (per DSM -V criteria, including drug or alcohol)  
26. Contraindications to head MRI (with contrast) or CT 
27. Pregnant or lactating  
28. Female patients of childbearing potential unwilling to use an adequate birth control method during the 12 months of the s tudy 
29. Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and conduct of the study  
30. Any prior SB623 cell i mplantation and/or any prior stem cell treatment for stroke or 
other reason regardless of mode of administration  
31. Subject is taking any prohibited medications (see Section 12.0)  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 28 of 86 8.0 INVESTIGATIONAL PLAN  
8.1 Overall Study Design  
This is a double -blind, sham -surgery controlled study of stereotactic, intracranial injection of 
SB623 cells in patients with fixed motor deficits from ischemic stroke.  The study will be 
conducted at approximately 65 sites in the United States.  
Two cohorts, Group 1 ( approximately 2.5 and approximately 5 million SB623 cells combined) 
and Group 2 (sham placebo), will be included in this study.  Subjects who are randomized into this study will receive either approximately 2.5 million SB623 cells, approximately 5 million 
SB623 cells or sham surgery at a 1:1:1 randomization ratio.  Randomization will be performed via an i nteractive web/voice response system (IXRS), stratified by Screening mRS score 
(recorded in the IXRS at the clinical site) . 
The study schematic is shown in the following figure.  
 
Figure  4: Study Schematic  
 
Note: Group 1 (Implant) will receive either  approximately  2.5 million SB623 cells or  approximately  5 million 
SB623 cells.  
Abbreviation: M  = million.  
 
The neurological assessment team evaluating Fugl -Meyer and other efficacy endpoints will be 
blinded, with the subjects also blinded.  The surgical team will remain unblinded, any 
communication between the surgical and neurological team (including the investigator) will be blinded. 
Safety will be monitored throughout the study.  In addition, an external Data Safety Monitoring 
Board will be utilized to review safety data, including clinical symptoms, laboratory findings, 
and MRI brain imaging.  Two or more serious adverse events potentially attributed to SB623 as 
assessed by the Investigator w ill trigger a review by the DSMB before continuing enrollment.  In 
addition, the DSMB will review the study for safety at 25% , 50% , and 75%  enrollment.  The 
DSMB shall be the final arbitrator for attributions.   

SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 29 of 86 Efficacy will be determined based on changes  in the clinical measures of stroke through 
standardized assessments (Fugl -Meyer Motor Scale (FMMS), Modified Rankin Scale (mRS), 
Action Research Arm Test (ARAT), Gait Velocity and two  sub- domains of the NeuroQOL 
scale).  MRI of the brain will be performed at scheduled time points (pre - and post -contrast T1 
weighted, dual echo, and FLAIR sequences). MRIs will be analyzed by a central reader post -
surgery and blinded reports will be sent back to the assessment site staff (excluding the 
assessment site efficac y assessor) without any accompanying images. Exploratory imaging (e.g. 
diffusion tensor imaging [DTI] and dynamic susceptibility contrast [ DSC ] MRI for perfusion 
imaging) will also be performed  at capable sites .   
The primary and secondary efficacy assessm ents will be completed solely by blinded study 
personnel that do not have access to patient study safety information (this include s adverse 
events, concomitant medications, progress notes, and MRI reports ). 
Stopping Rules:  
If the DSMB determines that continuation of enrollment in the trial provides an unreasonable 
risk to the patients, it may recommend study termination.  All SAEs, regardless of attribution 
shall be reviewed by the DSMB.  
In addition, adverse events attributable to the surgical procedur e, such as intracranial infection, 
intracranial bleeding, or seizures, shall be subject to review by the DSMB.  
The DSMB shall be the final arbitrator for attributions.  
8.2 Duration of Patient Participation  
Twelve months  post -surgery  (except if there is an unresolved adverse event of at least Grade 2 
and at least possibly related to the therapy, in which case the patient will be followed until resolved or reduced to Grade  1). 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 30 of 86 9.0 STUDY ASSESSMENTS  
9.1 Schedule of Study Activities  
Table 3 below  lists the procedures to be followed throughout the course of the study.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 31 of 86 Table 3:  Schedule of Assessments  
Study Period Screening  Baseline  Sham or Cell 
Admin  Follow -Up Period  
Study Visit Type  Assessment  Assessment  Surgical  Assessment  
Study Visit  1 2 3A1 3B 4 5 6 7 8 
Study Day  -84 to -22 -21 to -2 -1 1 2 8 
(± 1)  28 
(± 7)  84 
(± 7)  168 
(± 7)  
Study Week       1 4 12 24 
Study Month        1 3 6 
Informed Consent  X  X2       
Demographics  X         
Inclusion/Exclusion  X         
Eligibility Criteria Review3  X X       
Randomization     X      
Medical History  (including stroke history)  X         
Physical Therapy Instruction and  
Subject Exercise Diary given to subject  X     X X X X 
Subject Exercise Diary Review   X     X X X 
Leg Activity Monitor given to subject  X X    X X X X 
Collect Leg Activity Monitor   X    X X X X 
Pregnancy Test4 X X X      X 
Physical Exam  X X X      X 
Vital Signs  (weight and height  recorded at 
Screening only)  X X X X  X X X X 
Chest X -Ray and ECG  X  X      X 
Hematology  X  X3   X X X X 
Serum Chemistry  X  X3   X X X X 
INR X  X3      X 
HLA typing of each subject   X        
ApoE4 & BDNF Val66Met genotyping   X        
Serum for anti -HLA Antibodies5  X    X X X X 
PBMC Sample5  X    X X X X 
Occult Malignancy  X         
CESD -R Scale  X         
Head CT     X6      
Imaging --Head MRI7 X X  X8 X X X  X 
Motricity Index  X         
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 32 of 86 Study Period Screening  Baseline  Sham or Cell 
Admin  Follow -Up Period  
Study Visit Type  Assessment  Assessment  Surgical  Assessment  
Study Visit  1 2 3A1 3B 4 5 6 7 8 
Study Day  -84 to -22 -21 to -2 -1 1 2 8 
(± 1)  28 
(± 7)  84 
(± 7)  168 
(± 7)  
Study Week       1 4 12 24 
Study Month        1 3 6 
Imaging – Diffusion Tensor Imaging9  X     X  X 
Modified Rankin Score  (mRS)10 X11 X     X X X 
Fugl-Meyer Motor Score  (FMMS)10  X     X X X 
Action Research Arm Test  (ARAT)10  X     X X X 
Gait Velocity10  X     X X X 
NeuroQOL (2 subdomains)10  X     X X X 
Global Rating of Perceived Change 
(subject and clinician)  – 7-point Likert 
Scale10, 12      
 X X X 
Admission1   X       
Sham Surgery or Cell Administration13    X      
Discharge14     X     
Adverse Events15 X X X X16 X X X X X 
Concomitant Medications  X17 X X X16 X X X X X 
1 Pre-operative  procedures may be performed within 14 days of the surgery day and admission may occur on the day of surgery (Day 1) to accommodate 
scheduling . 
2  Confirmation of appropriate Informed consent . 
3 The assessment of a subject’s suitability for surgery will be performed at Visit  3A (Day -1) according to clinical site standard practice and Investigator 
judgement.  
NOTE: Hematology, Serum Chemistry, and IN R at admission (Visit  3A) are to be performed by both the central laboratory (for data collection purposes) 
and the local laboratory (to ensure subject is suitable for surgical procedure), all other on study laboratory assessments to  be done by central lab oratory 
only.  
NOTE: Post -operative visits may be conducted according to the surgical site’s standard of care.  
4 Only for women of childbearing potential.  Serum β -HCG at Screening (Visit 1), Visit 8, and Visit 10; either serum or urine β -HCG at Baseline (V isit 2) 
and Admission (Visit 3 A). 
5 At each timepoint that serum antibody samples are collected an additional sample for PBMC will also be collected and stored at the central laboratory . 
6 Head CT on Day 1 is post -operative . 
7 Magnetic Resonance Imaging (M RI) of the brain will be obtained using either a 1.5 or 3 Tesla MRI scanner.  Each subject should have all scans conducted 
on the same scanner if possible (excepting those used for stereotactic planning and post -operative assessments, within 2  weeks of the  surgery 
(implant/sham).  Standard T1 and T2 sequences  and FLAIR  will be obtained, and will be recorded in standard digital format for review.  Contrast is to be 
utilized for MRI procedures  at Baseline (Visit 2 ), Day of su rgery (Visit 3B), Day 8 (Visit 5),  Month 1 (Visit 6 ), and Month 12 (Visit 10) ; at these visits 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 33 of 86 Dynamic Susceptibility Contrast (DSC) imaging  will also be performed. A ll other scheduled MRI to be performed without contrast .  MRI within 3 months 
of Visit 1 is acceptable for Screening MRI.  
8 Or CT overlaid with MRI from Baseline .  Contrast is not to be utilized for CT procedures.  
9 Diffusion tensor imaging (DTI) is an MRI technique which characterizes the magnitude, anisotropy and orientation of the diffu sion tensor, using the 
pulsed -gradient,  spin echo pulse sequence with a single -shot, echo planar imaging readout .  DTI data will be obtained using whole brain coverage, a 
maximum of 2.5 mm isotropic resolution and at least 30 diffusion encoding directions and may be obtained using either a 1.5 or 3 Tesla MRI scanner . DTI 
is required for subjects at assessment sites with DTI capability. DTI is optional for sites without access to DTI -compatible scanners.  Perfusion imaging is 
also required for subjects at assessments sites when the MRI has the cap acity.  
10 All efficacy assessments will be completed solely by blinded study personnel that do not have access to patient study s afety information (this includes  
adverse events, concomitant medications, progress notes, and MRI reports).  
11 The mRS Screenin g value is to be recorded by the clinical site utilizing the IXRS.   
12 The subject global rating of perceived change should be completed by the subject. In the event the subject is not able to complet e the questionnaire, the 
caregiver will be allowed to as k the questions of the subject and complete the questionnaire using the subject’s answer(s) . 
13 Subjects will undergo study surgical procedure on Day 1 only after all other procedures for this visit have been completed . 
14 Subjects will be discharged on Day 2  unless complications require a longer stay . 
15 Adverse event collection begins from the time Informed Consent is provided.  
16 During the surgical visit, adverse events and concomitant medications will be recorded pre-  and post -surgery . 
17 Including p rior and concomitant medications at Screening.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 34 of 86 Table 3 : Schedule of Assessments (Continued)  
Study Period Follow -up 
Study Visit Type  Assessment  
Study Visit  9 10/ 
Early Termination  
Study Day  252 
(± 14)  336 
(± 14)  
Study Week  36 48 
Study Month  9 12 
Pregnancy Test1  X 
Physical Exam   X 
Physical Therapy Instruction and  
Subject Exercise Diary given to subject  X  
Subject Exercise Diary Review  X X 
Leg Activity Monitor Given to Subject  X  
Leg Activity Monitor Collected from Subject  X X 
Vital Signs  X X 
Chest X -Ray and ECG   X 
Hematology  X X 
Serum Chemistry  X X 
INR  X 
Serum for anti -HLA Antibodies2  X 
PBMC2  X 
Imaging --Head MRI3  X 
Imaging – Diffusion Tensor Imaging4  X 
Modified Rankin Score (mRS)5 X X 
Fugl-Meyer Motor Score (FMMS)5 X X 
Action Research Arm Test (ARAT)5 X X 
Gait Velocity5 X X 
NeuroQOL (2 subdomains)5 X X 
Global Rating of Perceived Change (subject and 
clinician) – 7-point Likert Scale5, 6 X X 
Adverse Events  X X 
Concomitant Medications  X X 
1 Only for women of childbearing potential, Serum β -HCG . 
2 At each timepoint that serum antibody samples are collected, an additional sample for PBMC will also be collected and stored at the central laboratory . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 35 of 86 3 Magnetic Resonance Imaging (MRI) of the brain will be obtained using either a 1.5 or 3 Tesla MRI scanner .  Each subject should have all scans conducted  
on the same scanner if possible (excepting those used for stereotactic planning and post -operative assessments, within 2 weeks of the surgery 
(implant/sham) .  Standard T1 and T2 se quences  and FLAIR  will be obtained, and will be recorded in standard digital format for review .  Contrast is to be 
utilized for MRI procedures  at Baseline (Visit 2), Day of surgery (Visit 3B), Day 8 (Visit 5), Month 1 (Visit 6), and Month 12 (Visit 10) ; at these visits, 
Dynamic Susceptibility Contrast (DSC) imaging  will also be performed.   All other scheduled MRI to be performed without contrast . 
4 Diffusion tensor imaging (DTI) is an MRI technique which characterizes the magnitude, anisotropy and orien tation of the diffusion tensor, using the 
pulsed -gradient, spin echo pulse sequence with a single -shot, echo planar imaging readout .  DTI data will be obtained using whole brain coverage, a 
maximum of 2.5 mm isotropic resolution and at least 30 diffusion e ncoding directions and may be obtained using either a 1.5 or 3 Tesla MRI scanner . DTI 
is required for subjects at assessment sites with DTI capability. DTI is optional for sites without access to DTI -compatible scanners. Perfusion imaging is 
also required for subjects at assessments sites when the MRI has the capacity.  
5 All efficacy assessments will be completed solely by blinded study personnel that do not have access to patient study s afety information (this includes  
adverse events, concomitant medications, progress notes, and MRI reports).  
6 The subject global rating of perceived change should be completed by the subject. In the event the subject is not able to com plete the questionnaire, the 
caregiver will be allowe d to ask the questions of the subject and complete the questionnaire using the subject’s answer(s).  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 36 of 86 9.2 Pre-study Evaluation and Baseline  
The following will be done prior to performing any study -specific procedures:  
Informed Consent Signed: study -related details will be carefully discussed with the patient.  
The patient will sign an Informed Consent Form approved by the local Ethics Committee. 
9.2.1 Visit 1: Scr eening  (Day -84 to - 22; Assessment Site ) 
The Medical Monitor will be consulted if any screening procedures may be conducted outside 
the specified Screening visit window (eg, due to operating room scheduling delay).  
• Inclusion/Exclusion Criteria  (refer to Appendix C for anticoagulant guidelines)  
• Demographics  
• Medical History  (including stroke history)  
• Prior and concomita nt Medications  
• Pregnancy Test (serum β -hCG)  for women of childbearing  potential only  
• Physical Therapy Instructions  and Subject Exercise Diary given to subject  
• Leg Activity Monitor Given to Subject  
• Physical Exam  
• Vital Signs  Including Weight  and Height  
• Ches t X-Ray 
• 12-lead ECG  
• Hematology   
• Serum Chemistry   
• INR 
• Determination of occult malignancy  
• CESD -R Scale Administration (subject must have score of <16) 
• Imaging ( head MRI ).  NOTE: MRI within 3 months of Visit 1 is acceptable for 
Screening MRI  as long as meets criteria (does not require DTI  or perfusion imaging ) 
• Clinical Stroke Evaluation  (Modified Rankin and  Motricity Index ) 
• Adverse events  
Subjects may be re- screened with the approval of the medical monitor. If during the screening or 
re-screening period, there i s a change in medical condition, additional, repeat, or unscheduled 
procedures may be performed at the Investigator’s discretion.  
9.3 Baseline and Confirmation of Eligibility  
9.3.1 Visit 2: Baseline ( Day - 21 to -2; Assessment Site ) 
The following will be performed at Baseline:  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 37 of 86 • Eligibility Criteria Review  
• Adverse events  
• Concomitant medications  
• Pregnancy Test (serum or urine β -hCG)  for women of childbearing  potential only  
• Physical Exam  
• Subject Exercise Diary Review  
• Collect Leg Activity Monitor  
• Re-issue Leg Activity Monitor  
• Vital Signs  
• HLA typing (molecular) of each subject  
• ApoE4 & BDNF Val66Met genotyping  of each subject  
• Blood draw for Serum anti-HLA Antibodies   
• Blood draw for PBMC  
• Imaging (head MRI)  
• Exploratory Imaging (Standard T1-  and T2 -weighted  MRI , and FLAIR ), and at sites 
with capability D iffusion tensor imaging  (DTI) with tractography  and perfusion 
imaging  (including DSC)  
• Clinical Stroke Evaluations  (FMMS; mRS; ARAT; Gait Velocity; NeuroQOL (Upper 
Extremity Function  and Lower Extremity Function ) 
9.3.2 Eligibility Confirmation  
Confirmation of eligibility can only occur after performing all assessments and verifying that the 
patient meets the inclusion and exclusion criteria for the study.  
9.4 Surgical Admission  (Visit 3 A: Day - 1; Surgical Site ) 
Pre-operative  procedures may be performed within 14 days of the surgery day and admission 
may occur on the day of surgery (D1) to accommodate scheduling . 
• Admission  
• Confirm Informed Consent  
• Review Eligibility Criteria to determine suitability for surgery  (according to clinical 
site standard practice and Investigator judgment)  
• Adverse events  
• Concomitant medications  
• Pregnancy Test (serum or urine β -hCG) for women of childbearing  potential only  
• Physical Exam  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 38 of 86 • Vital Signs  
• Chest X -ray 
• 12-lead ECG  
• Hematology  
• Serum Chemistry  
• INR 
9.5 Randomization and Cell Administration  or Sham Surgery (Visit 3B : Day  1; Surgical 
Site) 
Prior to any procedures, the patient will be queried on the use of any or changes in medication 
since Baseline.  
• Adverse events  
• Concomitant medications  
• Vital Signs  
• Imaging (head MRI or CT with MRI overlay)  
• Randomization  
 
Prior to cell implantation, either a head CT or a head MRI alone will be done to determine the 
exact locations for the implants.  
Group 1:  
One burr hole will be made in the skull of the patient in a location that will allow ready 
access to the infarct region.  Cells will be implanted using 3 needle tracks with 5  cell 
deposits for each track at varying depths.  Cell implantation will be standardi zed as to 
volume (20 µL/deposit) and rate (10 µL  /min) , with spacing between each implant of 
approximately 5 -6 mm.  
Group 2:  
Subjects will be given procedures similar to Group 1, except will be given a sham surgery (light sedation, stereotactic procedure,  partial- thickness skull outer table burr hole, scalp 
suture, but no penetration of inner table or dura mater) . 
After cell implantation  or sham surgery , the following will be performed:  
• Imaging (head CT only)  
• Adverse Events  
• Concomitant medications  
9.6 Visit 4: Follow -Up Period  (Study Day 2; Surgical Site )  
The following will be performed at the surgical site : 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 39 of 86 • Adverse Events  
• Concomitant Medications  
• Head MRI  
• Discharge  
NOTE: If additional days are required in the clinic, adverse events and concomitant 
medications w ill be monitored and recorded. Post -operative visits may be scheduled as 
required by the site’s standard of care . 
9.7 Visit 5: Follow -Up Period ( Week  1, Study Day 8 ± 1 ; Assessment Site ) 
The following will be performed:  
• Adverse Events  
• Concomitant Medications  
• Vital Signs  
• Hematology   
• Serum Chemistry   
• Physical Therapy Instructions  and Subject Exercise Diary given to subject  
• Collect Leg Activity Monitor  
• Re-issue Leg Activity Monitor  
• Blood draw for Serum anti -HLA Antibodies  
• Blood draw for PBMC  
• Head MRI  (MRI must be read before re -starting any antiplatelet, anticoagulant, or 
non-steroidal anti- inflammatory agents)  
9.8 Visit 6: Follow -Up Period  (Month 1, Study Day 28 ± 7; Assessment Site ) 
• Adverse Events  
• Concomitant Medications  
• Vital Signs  
• Hematology   
• Serum Chemistry  
• Blood draw for Serum anti -HLA Antibodies  
• Blood draw for PBMC  
• Subject Exercise Diary Review  
• Physical Therapy Instructions  and Subject Exercise Diary given to subject  
• Collect Leg Activity Monitor  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 40 of 86 • Re-issue Leg Activity Monitor  
• Imaging (head MRI)  
• Exploratory  Imaging (Standard T1-  and T2 -weighted MRI , and FLAIR ), and at sites 
with capability D iffusion tensor imaging  (DTI) with tractography  and perfusion 
imaging  (including DSC)  
• Clinical Stroke Evaluations  (FMMS; mRS; ARAT; Gait Velocity; NeuroQOL (Upper 
Extremity Function and  Lower Extremity Function ) 
• Global Rating of Perceived Change: subject and clinician , 7-point Likert scale  
9.9 Visit 7: Follow -Up Period ( Month 3, Study Day 84 ± 7; Assessment Site ) 
• Adverse Events  
• Concomitant Medications  
• Vital Signs  
• Hematology   
• Serum Chemistry   
• Blood draw for Serum anti -HLA Antibodies  
• Blood draw for PBMC  
• Subject Exercise Diary Review  
• Physical Therapy Instructions  and Subject Exercise Diary given to subject  
• Collect Leg Activity Monitor  
• Re-issue Leg Activity Monitor  
• Clinical Stroke Evaluations (FMMS; mRS; ARAT; Gait Velocity; NeuroQOL (Upper 
Extremity Function  and Lower Extremity Function ) 
• Global Rating of Perceived Change: subject and clinician, 7- point Likert scale   
9.10 Visit 8: Follow -Up Period ( Month 6, Study Day 168 ± 7 ; Assessment Site ) 
• Adverse Events  
• Concomitant Medications  
• Pregnancy test  (serum β -hCG) for women of childbearing potential only  
• Physical Exam  
• Subject Exercise Diary Review  
• Physical Therapy Instructions  and Subject Exercise Diary given to subject  
• Collec t Leg Activity Monitor  
• Re-issue Leg Activity Monitor  
• Vital Signs  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 41 of 86 • Chest X -ray 
• 12-lead ECG  
• Hematology   
• Serum Chemistry   
• INR 
• Blood draw for Serum anti -HLA Antibodies  
• Blood draw for PBMC  
• Imaging (head MRI)  
• Exploratory Imaging (Standard T1-  and T2 -weighted MRI , and FLAIR ), and at sites 
with capability D iffusion tensor imaging  (DTI) with tractography  and perfusion 
imaging  (including DSC)  
• Clinical Stroke Evaluations (FMMS; mRS; ARAT; Gait Velocity; NeuroQOL (Upper 
Extremity Function  and Lower Extremity Functio n) 
• Global Rating of Perceived Change: subject and clinician, 7- point Likert scale  
9.11 Visit 9: Follow -Up Period ( Month 9, Study Day 252 ± 14; Assessment Site ) 
• Adverse Events  
• Concomitant Medications  
• Vital Signs  
• Hematology  
• Serum Chemistry   
• Subject Exercise Diary Review  
• Physical Therapy Instructions  and Subject Exercise Diary given to subject  
• Collect Leg Activity Monitor  
• Re-issue Leg Activity Monitor  
• Clinical Stroke Evaluations (FMMS; mRS; ARAT; Gait Velocity; NeuroQOL (Upper 
Extremity Function  and Lower Ext remity Function ) 
• Global Rating of Perceived Change: subject and clinician, 7- point Likert scale  
9.12 Visit 10 /Early Termination : Follow -Up Period ( Month 12, Study Day  336 ± 14; 
Assessment Site ) 
• Adverse Events  
• Concomitant Medications  
• Pregnancy test  (serum β -hCG ) for women of childbearing potential only  
• Serum Chemistry  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 42 of 86 • Subject Exercise Diary Review  
• Collect Leg Activity Monitor  
• Vital Signs  
• Chest X -ray 
• 12-lead ECG  
• Hematology   
• Serum Chemistry   
• INR 
• Blood draw for Serum anti -HLA Antibodies  
• Blood draw for PBMC  
• Imaging (head MRI)  
• Exploratory Imaging (Standard T1-  and T2 -weighted MRI , and FLAIR ), and at sites 
with capability D iffusion tensor imaging  (DTI) with tractography  and perfusion 
imaging  (including DSC)  
• Clinical Stroke Evaluations (FMMS; mRS; ARAT; Gait Velocity; NeuroQOL (Upper 
Extremity Function  and Lower Extremity Function ) 
• Global Rating of Perceived Change: subject and clinician, 7- point Likert scale   
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 43 of 86 10.0 DESCRIPTION OF STUDY TREATMENT 
10.1 Study Product  Description  
The investigational product, SB623 cells, are s terile cell suspension in unit volume of 1 mL, 
containing ≥8 X 106 cells/mL, cryopreserved in CryoStore™ freezing media in a 2  mL vial. 
10.2 Study Product  Packaging and Labeling  
The investigational product, SB623 cells, are provided to clinical sites in unit volume of 1 mL 
suspension,  packaged and cryopreserved in CryoStore™ freezing media in a 2 mL Nalgene™  
cryovials with a Teflon® seal closure.  The vials are labeled at minimum with the following 
information:  
• Product Name (SB623)  
• Manufacture Lot. Number  
• Vial number  
• Sponsor Name and Address  
• Manufacturer Name and Address  
• Storage Conditions  
• Investigational Drug Statement in accordance with 21CFR312.6 
10.3 Study Product Shipment and Storage  
The cryovials containing the frozen cell suspensions are shipped in a dry nitrogen shipper and should be  stored in the vapor phase (≤  -150 
oC) within the shipping container provided by the 
Sponsor until transferred at the site to a GMP -compliant liquid nitrogen container .  At the 
clinical site, the investigational product should be  stored in the vapor phase (≤  -150 oC) within 
the liquid nitrogen container.  
The Sponsor will arrange for Study Product to be shipped to the clinical site. 
10.4 Preparation and Administration  
Details for preparation of the cell suspension for administration and f or loading the syringe in the 
Operation Room will be provided by the Sponsor to the clinical site unblinded personnel who 
will performed the cell target concentration preparation, labeling, administration and 
accountability of investigational product .  Det ailed information will be provided separately from 
this protocol in a n Investigational Product Manual.  Clinical sites will be provided with the 
necessary materials for reconstitution of the cells and will be trained by the Sponsor.  
The cryopreserved cell s will be thawed, washed, centrifuged, and re -suspended in Plasma -Lyte 
A to achieve target concentrations of approximately  2.5 X  106 cells/  0.3 mL and approximately 
5 X 106 cells/  0.3 mL, respectively.  The formulated dose for injection is packaged individually 
in 1.0 mL conical Nalgene ™ vi als with a Teflon seal closure.  
Prior to administration, a gram stain and a test for endotoxin will be done and a sterility test 
initiated on the last cell wash to insure continued sterility for release of target concentrations.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 44 of 86 The formulated dose for injection must be administered to the patient within 3  hours  post release 
testing.   
If the endotoxin level is > 5 EU/mL or the gram stain is positive, implantation will not occur.  If 
the sterility test is positive, an investigation will be conducted to determine the source of the 
contamination.  In addition, identification of the pathogen and sensitivity will be done and the 
patient treated with an appropriate antibiotic.  In this event, the patient will be followed clo sely 
for adverse events associated with a possible infection and response to antimicrobial therapy, 
including frequent clinic visits until any infection is cleared . 
10.5 Study Product  Accountability Procedures  
The Investigator will be responsible for maintaining inventory and accounting for all Study Product received from the Sponsor.  The investigator will be responsible for the accountability of target concentrations prepared and actually used for dosing for a subject .  After reconciliation 
has been completed, all unused Study Product vials received by the Investigator will be returned to the Sponsor in a dry nitrogen shipper stored in the vapor phase.  All vials (used or unused [ie, resuspended cells] ) are to be returned to the cell laboratory for reconciliation destruction. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 45 of 86 11.0 TREATMENT ASSIGNMENT  AND BLINDING  
This is a double -blind study.  Subjects will be randomized in a 1:1:1 ratio via an IXRS, stratified 
by Screening mRS score.  Each subject will be randomized at a surgical site prior to the surgica l 
procedure after study eligibility is confirmed.  The randomization will be balanced, in terms of 
numbers of subjects between the treatment groups, within each surgical site.  
The blind will be maintained by role definition and procedures described below:  
 
Unblinded personnel:  
• Cell preparation staff  
• Unblinded study coordinator  
• Surgeon and Operating Room staff  
• Designated unblinded sponsor & clinical research organization ( CRO ) personnel  
• Data and Safety Monitoring Board (DSMB) members and the supporting stati stician and 
programmer involved in regular review and generation of unblinded safety data  
 
Blinded personnel:  
• Assessment site staff  
• Designated blinded sponsor & CRO personnel  
In order to maintain the blind the following procedures will be implemented: 
1. Unblinded cell preparation staff will prepare and  perform  a quality check  of the cell 
suspension for each subject .  The identity of the treatme nt will be c oncealed by the 
preparation of  study product that is  identical in packa ging, labeling, schedule of 
administra tion, a dministr ation, a nd appearance. 
2. The neurosurgeon and Operating Room ( OR) staff will perform  the sham surgery 
procedure using a surgical script that mimic s the cell a dminist ration pr ocedure as closely 
as possibl e (e.g. sequence of steps and overall time taken in the OR) . 
3. Subjects, assessment site  staff, persons performing the assessments, blinded s ponsor  staff , 
and blinded CRO staff  will remain blind to the identity of the treatment from the time of 
randomization until database lock and unblinding, using the following methods : 
a. Randomization data are kept strictly confidential until the time of unblinding, and 
will not be accessible b y any of the blinded study personnel  in the study , unless 
subject level emergency unblinding is required as noted in section 11.1 Emergency Unblinding Procedures . 
b. MRIs will be analyzed by a central reader post -surgery and blinded reports will 
be sent back to the assessment site staff (excluding the Assessment site efficacy assessor) w ithout any accompanying images.   Description of the craniotomy skull 
defect and needle tract from the stereotactic surgical procedure are unblinding by 
definition and will ther efore be excluded from the blinded head MRI reports.  If 
an unscheduled head MRI is to be done, the same process shall be followed as for 
the scheduled head MRI scans to maintain blinding, unless a local read is 
necessary for clinical care per a ssessment site investigator’s discretion.  These 
unblinding events will be recorded and reported to the Sponsor .  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 46 of 86 c. To further safeguard maintenance of the blind, all  efficacy assessments are to be 
completed solely by the  efficacy assessor s at assessment site s, who wil l be 
segregated from other activities at the assessment site and not have access to any 
patient study safety information (e.g. adverse events, concomitant medications, head  imaging  reports , and medical charts etc. ). 
d. All sites will be trained on Maintenance  of the blind procedures and the training 
will be documented prior to site activation . 
The following are the exceptions  to those staff required to remain blinded: Data and Safety 
Monitoring Board (DSMB) members involved in regular review of safety data, unblinded cell preparation staff, unblinded neurosurgeon and OR surgical staff, unblinded study monitor . 
11.1 Emergency Unblinding Procedures  
The blinded treatment ass ignment/dose information is to be broken only in an emergency when 
knowledge of such treatment may have an impact on further treatment decisions or aid in the emergency treatment of the subject .  The Investigator will obtain the treatment assignment for 
the specified subject by accessing the IXRS .  Date and reason for unblinding are to be promptly 
communicated via telephone and in writing to the Medical Monitor and documented in the CRF . 
Any subject for whom the treatment assignment/dose information was unblinded should continue to follow study procedures . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 47 of 86 12.0 CONCOMITANT MEDICATI ONS  
The following medications should not be used during participation in the study:  
• Bupropion (Wellbutrin®, Zyban®, others)  
• Tricyclic Antidepressants (includes amitryptilene, nortryptilene, clomipramine, others)  
• Clozapine (Clozaril®)  
• Tramadol (Ultram®, Ultracet®)  
• Meperidine (Demerol®)  
• Theophylline (Theolair®, Slo- Bid®, Aminophylline, others)  
• Cyclosporin  
 
All concomitant medications including prescription and over -the-counter drugs taken during the 
14 days prior to enrollment or used anytime during the study through 12 months  post -Study 
Product  (ie, End of Study) or Early Termination will be documented.  Documentation will  
include changes from the prior visit, start and stop dates, dose, and reasons for the medication 
use. 
Investigational drugs or devices for any other indication are not allowed during the study.  
Refer to Appendix C for anticoagulant guidelines.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 48 of 86 13.0 STUDY WITHDRAWAL/TERMINATION 
13.1 Study Termination 
The protocol may be terminated at any time  by the Sponsor in the event of significant Study -
Drug -related adverse effects.  
13.2 Site Termination  
The study site will be closed if there is evidence of fraud, other unethical conduct, or significant 
non-compliance to the protocol or to Good Clinical Practices (GCPs).  Should patient enrollment 
be unsatisfactory, or data recording be inaccurate and/or incomplete, the Sponsor may terminate 
the study and remove all study materials from the study site.  
13.3 Patient Discontinuation  
Patients will be fre e to discontinue from the study at any time without giving reason(s).  Patients 
will be considered discontinued from the study in the event of any of the following reasons:  
• Withdrawal of the patient’s consent for any reason  
• Investigator’s discretion due to patient’s medical condition  
If patient withdrawal occurs during the study period, the Last Evaluation visit should be performed, whenever possible, at the time of patient withdrawal or as soon as possible.  If 
possible, the  Investigator should attempt to evaluate the medical condition for 12 months  
post-surgery for any patient who has withdrawn (provided the patient consents to such 
follow -up). 
In the event a patient withdraws from the study for any reason, the Investigator must 
notify the Principal Monitor by telephone within 24  hours of withdrawal.  
13.4 Patients Lost to Follow Up  
Patients who cannot be reached after at least three attempts will be categorized as lost to follow up.  The attempts to reach the patients must be documented, with at least one of the attempts written and sent to the patient via  certified or registered mail.  Patients lost to follow up will still 
be included in the analysis of the study .  For patients lost to follow up, the Investigator will be 
asked to check public records for s urvival status at 12 months  when possible . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 49 of 86 14.0 STOPPING R ULES  
If the DSMB determines that continuation of enrollment in the trial provides an unreasonable 
risk to the patients, it may recommend study termination.  All SAEs, regardless of attribution 
shall be r eviewed by the DSMB.  
In addition, adverse events attributable to the surgical procedure, such as intracranial infection, 
intracranial bleeding, or seizures, shall be subject to review by the DSMB . 
The DSMB shall be the final arbitrator for attributions.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 50 of 86 15.0 CLINICAL AND LABORAT ORY EVALUATIONS AND PROCEDURES  
15.1 Medical History  (Including Stroke History)  
Medical history (including stroke history) will include significant medical conditions and 
surgical history, medications taken within 2 weeks prior to signing the  Informed Cons ent. 
15.2 Physical Examination and Vital Signs  
A complete physical examination will be performed (including a genital/rectal exam if clinically 
indicated).  
Vital signs will include oral temperature, blood pressure at rest (while subject is in seat ed 
position) , heart rate, and respiratory rate. W eight  and height  will be recorded at screening  only . 
15.3 Safety Laboratory 
All safety laboratory evaluations will be conducted at a  central laborator y (except at surgical 
visit) .  At every sampling time point, approximately 15 mL of blood will be drawn for each of 
the hematology and serum chemistry panels .  Detailed information regarding collection of blood 
samples for clinical safety laboratory evaluations will be provided separ ately from this protocol.  
The following laboratory evaluations will be performed:  
• Hematology Panel: hematocrit, hemoglobin, WBC, platelet count,  absolute  
lymphocyte count, absolute neutrophil count  
• Serum Chemistry Panel: sodium, chloride, calcium, potassium, magnesium, 
creatinine, BUN, AST, ALT, alkaline phosphatase, and total bilirubin 
• INR 
15.4 Pregnancy Test: Serum or urine β-hCG  
• Serum β-hCG at Screening  (using same blood draw as for serum chemistry) , Visit 8, 
and Visit  10 
• Serum β-hCG or Urine β-hCG at Baselin e and Admission (Visit 3A)  
Detailed information regarding collection of samples for pregnancy testing will be provided 
separately from this protocol. 
15.5 HLA typing  and ApoE4 and BDNF Val66Met Genotyping  
HLA typing (molecular) of each subject will be performed at baseline to allow exploratory 
analysis of degree of mismatch to SB623 with respect to both efficacy and safety.  
Genotyping at the ApoE locus (ie, to determine if patient is homozygous for ApoE4, E2 or  E3, or 
if patient is heteroz ygous for E2/E3, E3/E4 or  E2/E4 ) will be performed at baseline.  
Assessment of whether BDNFVal66Met mutation is present ( yes/no ) will be performed at 
baseline.  
A central laboratory will be utilized for sample storage and assay .  Detailed information 
regarding collection of sample s will be provided separately from this protocol. 
The samples will be stored for at least 15 years to allow for post marketing analysis.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 51 of 86  
15.6 Serum Anti -HLA Antibodie s 
Anti-HLA s erum antibody measurements will be made to monitor a possible humoral -mediated 
immune response.  Blood samples will be taken at the intervals indicated in the schedule of 
assessments for measurements of serum anti -HLA antibodies using the Luminex assay  and for 
storage .  Assays will be done periodically on pooled samples .  A central labo ratory will be 
utilized for sample storage and assay .  Detailed information regarding collection of samples will 
be provided separately from this protocol. The samples will be stored for at least 15  years to allow for post marketing analysis.  
 15.7 PBMC Samples  
At each timepoint that serum antibody samples are collected, an additional sample for PBMC 
will also be collected .  A central laboratory will be utilized for sample storage .  Detailed 
information regarding collection of samples will be provided separately  from this protocol. 
The samples will be stored for at least 15  years to allow for post marketing analysis.  
 
15.8 Occult Malignancy  
Occult Malignancy will be determined by occult blood in stools (hemocult  test), finding on chest 
x-ray, carcinoembryonic antigen, prostate -specific antigen (males only), cancer antigen  125 
(females only), α -fetoprotein, and β -hCG.  
15.9 CESD- R 
The Center for Epidemiologic Studies Depression Scale Revised will be used for screening f or 
depression and depressive disorder.  
15.10 Clinical Stroke Evaluations  
Detailed information regarding clinical stroke evaluations (including sample forms and 
instructions for conducting the evaluations) will be provided separately from this protocol. 
 Fugl -Meyer Motor Score  (FMMS) 
FMMS will be calculated as change from baseline for Months  1, 3, 6 (primary), 9 and 12.  The 
treatment group will be compared to the control group based on the relative proportion of 
subject s who improve  at least 10  points. 
 
Modified Rankin Scale  (mRS) 
The mRS will be calculated to determine eligibility (mRS  2-4) at screening and again at 
Baseline, Months  1, 3, 6 (secondary), 9 and 12 months .  The treatment group will be compared to 
the control group based on based on the relative proportion of subjects who improve at least 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 52 of 86 1 point.  The mRS for all assessments except the Screening assessment will be recorded on video 
and reviewed in a blinded fashion by a central external rater . 
 
Motricity Index  
To ensure subjects have a define d motor deficit, an assessment of the subject’s Motricity Index 
will be calculated at Screening for study eligibility purposes .  Subjects will r equire either  
Motricity Index 30- 75 (U pper E xtremity  Scale) OR  27-74 (L ower Extremity  Scale) .  
 
Action Research A rm Test  (ARAT)  
ARAT scores  will be calculated at Baseline and  Months  1, 3, 6 ( secondary ), 9 and 12.  The 
treatment group will be compared to the control group based on the relative proportion of 
subjects who improve at least 6 points. 
 Gait Velocity  
Gait Velocity on a standard 10 m walk will be calculated at Baseline and  Months  1, 3, 6 
(secondary ), 9 and 12.  The treatment group will be compared to the control group based on the 
relative proportion of subjects who improve at least one functional level (e.g. from < 0.4 m/s to 
0.4-0.8 m/s or from 0.4- 0.8 m/s to > 0.8 m /s). 
 NeuroQOL  
Two subdomains of the NeuroQOL will be assessed at Baseline and Months  1, 3, 6 ( secondary), 
9 and 12 using the Short Forms .  The 2 subdomains include: Upper Extremity Function (Fine 
motor ADL)  and Lower Extremity Function (Mobility) .  The treatment group will be compared 
to the control group based on the mean change in T Scores from baseline.  
 Global Rating of Perceived change from Baseline  
This assessment will be performed at Months  1, 3, 6 (secondary), 9 and 12.  It will be performed 
by both subject (may be completed by caregiver) and clinician .  Subjects and clinicians will be 
asked about perceived changes in their motor function by comparing “how well they are doing 
compared  to before the surgical procedure ”.  The subject global rating of perceived change 
should be completed by the subject. In the event the subject is not able to complete the 
questionnaire, the c aregiver will be allowed to ask the questions of the subject and complete the 
questionnaire using the subject’s answer(s) . The following 7- point Likert scale will be used:  
• Score 7 = Much better  
• Score 6 = A little better, meaningful 
• Score 5 = A little better, not meaningful  
• Score 4 = About the same  
• Score 3 = A little worse, not meaningful  
• Score 2 = A little worse, meaningful 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 53 of 86 • Score 1 = Much worse  
15.11 Physiotherapy  
Subjects will be instructed on of a set of exercises (cylinder grasp, thumb raise, stand and squat, 
walk)  to be carried out at home every morning and afternoon while in the study .  Subjects will be 
asked to keep a daily diary of their performance of the exercises.  
Physical therapy treatment during the study will be recorded in the CRF.  
15.12 Leg Activity Monitoring 
Bilateral ankle sensors will be worn by subj ects for 2  week intervals at Screening (Day  -14), 
Baseline (Day - 1) and Months  1, 3, 6, and 9.  Data will be provided to a centralized reviewer for 
analysis .  Detailed information regarding leg activity monitoring  will be provided separately 
from this prot ocol. 
15.13 Imaging (MRI), Chest X -Ray, CT, and ECG  
MRI  
Magnetic Resonance Imaging (MRI) of the brain will be obtained using either a 1.5 or  3 Tesla 
MRI scanner .  Each subject should have all scans conducted on the same scanner if possible 
(excepting those used for stereotactic planning and post -operative assessments, within 2 weeks 
of the surgery (implant/sham) .  Standard T1 and T2 sequences  and FLAIR  will be obtained, and 
will be recorded in standard digital format for review .  Contrast is to be utilized for MR I 
procedures  at Baseline (Visit 2), Day of surgery (Visit 3B), Day 8 (Visit 5), Month 1 (Visit 6), 
and Month 12 (Visit 10); all other scheduled MRI to be performed without contrast . 
Diffusion tensor imaging (DTI) is an MRI technique which characterizes the  magnitude, 
anisotropy and orientation of the diffusion tensor, using the pulsed- gradient, spin echo pulse 
sequence with a single- shot, echo planar imaging readout .  DTI data will be obtained using 
whole brain coverage, a maximum of 2.5 mm isotropic resolution and at least 30 diffusion 
encoding directions and may be obtained using either a 1.5 or 3 Tesla MRI scanne r. DTI is 
required for subjects at assessment sites with DTI capability. DTI is optional for sites without 
access to DTI -compatible scanners . Perfusion imaging , including DSC, is also required for 
subjects at assessment sites when the MRI has the capacity.  
A centralized imaging core laboratory will be used to confirm  lesion size  for analysis purposes , 
develop imaging acquisition protocols, and conduct imaging processing and analyses .   
Detailed information regarding MRI procedures will be provided separately from this protocol.  
Chest X -ray 
Standard chest x -ray techniques will be performed according to the schedule described above.  
 
CT Scans  
Standard  CT techniques will be performed according to the schedule described above .  CT is to 
be conducted without contrast. 
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 54 of 86 Electrocardiograms  
All ECGs will be obtained in the supine position, after the subject has been resting supine for at 
least 10 minutes .  ECGs will be 12  lead with a 10  second rhythm strip.  ECGs should be obtained 
prior to drawing blood samples .  With the exception of Visit 3 ECG, a ll attempts should be  made 
to use the same ECG recorder for all visits within individual subjects .  ECGs will be centrally 
read at a core lab according to established quality assurance procedures for inter/intra reader 
variability .  ECGs will be reviewed, signed and dated by the  Investigator listed on the Form 
FDA  1572 (MD or DO) after each ECG collection .  The same Investigator should review all 
ECG reports for a given subject whenever possible . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 55 of 86 16.0 ADVERSE EVENTS  
16.1 General Information  
An adverse event  (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject enrolled in the study and that d oes not necessarily have a causal relationship with this 
treatment.  An AE can therefore be any unfavorable and unintended sign, symptom, or disease 
temporally associated with the use of an investigational product, whether or not considered related to the investigational product.  This includes any side effects, injury, toxicity, or 
sensitivity reaction, and may include a single symptom or sign, a set of related symptoms or 
signs, or a disease.  An adverse event is also any laboratory abnormality judged to be clinically significant by the Investigator or Sub- investigator(s) that worsened compared to Baseline.  
Throughout the course of the study, every effort should be made to remain alert to possible adverse experiences.  Patients should be encouraged to report adverse events spontaneously or in response to general, non- directed questioning.  
With the occurrence of an adverse event, the primary concern is the safety of the patient.  If necessary, appropriate medical intervention should be provided.  
An AE does n ot include:  
• Medical or surgical procedures ( e.g., surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure is an adverse event  
• Pre-existing diseases or conditions present or detected at the start of the study that do 
not worsen in severity or frequency  
• Situations where an untoward medical occurrence has not occurred ( e.g., 
hospitalization for elective surgery, social and/or convenience admissions)  
• Overdose of concomitant medication without any signs or symptoms  
A Serious  Adverse Event (SAE)  is any adverse event that results in any of the following:  
• death,  
• life-threatening event,  
• hospitalization or prolongation of hospitalization, 
• a persistent or significant disability/incapacity,  
• congenital anomaly/birth defect, or  
• an event that may require intervention to prevent any one of the other outcomes listed above (based on medical judgment)  
An Unexpected Adverse Event is any AE that is not identified in nature, severity, or frequency in the current Investigator’s Brochure or p roduct information. Adverse events assessed as related to 
surgical procedure, and Clavien- Dindo Classification 
(http://www.surgicalcomplication.info/index -2.html) Grade II or higher would be considered 
unexpected or unanticipated, unless such event has bee n previously reported and documented in 
the IB . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 56 of 86 A Serious and Unexpected Suspected Adverse Reaction (SUSAR) is an adverse reaction to study 
product or surgical procedure that is both serious and unexpected and for which there is a 
reasonable possibility th at the study product or surgical procedure caused the adverse event.  
All SUSARs will be submitted as expedited reports to the FDA.  For this study, serious and 
unexpected AEs involving neurological deterioration, procedural complications, seizures, benign 
and malignant tumors and pregnancy will also be submitted as expedited reports, regardless of 
attribution.  
16.2 Adverse Event Reporting Period  
The adverse event reporting period for this trial begins upon informed consent and ends 
12 months  after the administra tion of SB623, or at Early Termination . 
All AEs (both serious and non- serious) should be followed until resolution or until a stable 
clinical endpoint is reached.  All measures required for AE management and the ultimate 
outcome of the AE must be recorded in the source document. 
16.3 Recording of AEs  
All AEs, regardless of severity, seriousness, or presumed relationship to Study Product , must be 
recorded using medical terminology in the source document and on the CRF.  Events will be 
recorded at all study sites using standard terminology provided by the Sponsor or designate ( e.g., 
CRO), such as MedDRA  terminology.  
The WHO (World Health Organization) Standard Toxicity Criteria (STC) will be used to assist in categorizing and grading adverse events.  A copy of the WHO STC will be provided in the 
study documents.  Whenever possible, a diagnosis should be given when signs and symptoms are due to common etiology ( e.g., cough, runny nose, sneezing, sore throat, and head congestion 
should be reported as “upper respirator y infection”). 
16.4 Assessing Relationship of AE to Study Product  
The Investigator must record his/her opinion concerning the relationship of the AE to study therapy on the Adverse Event CRF.  Table 4 below provides guidance for assigning relationship 
to Study Product . 
Table 4:  Relationship of Adverse Event to the Administration of the Study Product or 
Surgery  
Not related  No temporal relationship to cell treatment/procedure, or the presence of a reasonable 
causal relationship between another drug, concurrent disease, or circumstance and the 
adverse event (AE).  
Unlikely 
related  A temporal relationship to cell treatment/procedure, but no reasonable causal relationship between cell treatment/procedure and the AE.  
Possibly 
related  A reasonable causal relationship between the cell treatment/procedure and the AE .  
Information related to withdrawal of cell treatment/procedure was lacking or unclear.  
Probably related  A reasonable causal relationship between the cell treatment/procedure and the AE .  The 
event responded to withdrawal of cell treatment/procedure .   
Definitely related  A reasonable causal relationship between the cell treatment/procedure and the AE .  The 
event responded to withdrawal of the cell treatment/procedure . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 57 of 86  
16.5 Reporting Serious Adverse Events  
Any Serious Adverse Event, including death that occurs during this study, whether or not the 
event is considered to be related to the study product or surgical procedure , must be reported 
immediately (within 24  hours after the site becomes aware of the event)  to the Safety Monitor  
(ProPharma Group/ PROSAR) . 
 
The contact information for reporting SAEs is as follows:  
Safety Monitor:  Tim Smith, PharmD, BSN ( ProPharma Group/ PROSAR)  
Email: drugsafety@prosarcorp.com  
FAX: 866 -681-1063  
The Investigator is encouraged to discuss with the Unblinded Medical Monitor any adverse 
experiences for which the issue of reportability is unclear or questioned.  
A verbal SAE notification must be followed by a completed Serious Adverse Event Report f orm 
signed by the Investigator within 24 hours. The report should be as complete as possible without 
delaying ProPharma Group/PROSAR notification.  
Any SAE follow-up information requested by ProPharma Group/PROSAR should be provided in a 
timely manner . 
Upon receipt of notification of any Serious Adverse Event, ProPharma Group/ PROSAR, the 
Unblinded Medical Monitor and the Sponsor  will immediately conduct an evaluation of the 
event and take action indicated by the results of the evaluation.  This may include notification to 
applicable regulatory authorities/federal agencies,  other Investigators, IRBs and/or the 
suspension or termination of the study.  The Sponsor will remain blinded during this process. 
The Investigator is required to report all IND Safety Reports to the local Ethics Committee (EC) 
or Institutional Review Board (IRB) /Institutional Biosafety Committee (IBC)  in accordance with 
the EC/IRB bylaws.  
All additional follow -up evaluations of the SAE must be reported to ProPharma 
Group/ PROSAR .  These data should be sent by email as scanned copy  or faxed to the Safety 
Monitor at 866- 681-1063  as soon as they are available.  
16.6 Follow -up of Adverse Events  
All AEs (both serious and non- serious) should be followed until resolution or until a stable 
clinical endpoint is reached. All measures required for AE management and the ultimate 
outcome of the AE must be recorded in the source document . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 58 of 86 17.0 EXTERNAL DATA SAFETY MONITORING BOARD 
An External Data Safety Monitoring Board (DSMB) will evaluate safety and to xicity and 
mortality rates, and recommend appropriate actions, according to the DSMB Charter .  The 
DSMB will review ongoing study data within one month of the enrollment of subjects at the 
25%, 50%, and 75% of the total population.  In addition, t wo or mor e serious adverse events 
potentially attributed to SB623 as assessed by the Investigator will trigger a review by the 
DSMB before continuing enrollment. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 59 of 86 18.0 STATISTICAL METHODS  
18.1 Analys is Populations  
18.1.1 Efficacy Population 
The intent -to-treat (ITT) population will include all randomized patients .  All efficacy analyses  
will utilize this population.  
18.1.2 Safety Population 
The safety population will include all randomized patients that  undergo surgery.  All safety 
analyses will utilize this population.  
18.2 Statistical Analysis  
The Statistical Analysis Plan (SAP) will provide details on the statistical methods planned for 
this study , and it will be finalized prior to  the clinical study database is locked and the treatment 
is unblinded. 
In general, demographics and baseli ne characteristics will be  presented by treatment group .  
Continuous variables will be  summarized by the following descriptive statistics: sample size, 
mean, median, standard deviation, minimum, and maximum .  Discrete variables will be  
summarized by freque ncies and percentages (contingency tables).  
18.2.1 Analysis of Efficacy  
All efficacy analyses will be performed on the modified intention to treat (m ITT) population, 
which is defined as all randomized patients who complete the surgery treatment procedure (or 
sham ). 
18.2.1.1 Primary Efficacy Analysis  
The primary analysis will be a comparison of the proportion of SB623 treated subjects ( pooling 
both SB623 doses) to sham surgical controls that achieve a n improvement of at least 10  points on 
the Fugl -Meyer Motor Scale at 6  months  from Baseline.  A generalized linear mixed model 
(GLMM)  will be utilized using the m ITT population.  The GLMM model will have the outcome 
variable, r esponder of FMMS (either ≥ or < 10 points improvement in FMMS at Month 6), and 
independent variables  of treatment  (SB623 combined doses vs. sham surgical control) , FMMS 
baseline score and pooled surgical  site as fixed effect s. 
Hypothesis  
Let PSB62 3_ combined doses  and P Placebo represent the proportions of responders who have an 
improvement of at least 10  points  on the Fugl -Meyer Motor Scale at 6  months  from Baseline in 
SB623 combined doses and placebo, respectively .  The primary analysis will test the following 
hypothesis  
H0: PSB62 3_ combined doses = PPlacebo versus the alternate H 1: PSB623 _ combined doses ≠  PPlacebo  
18.2.1.2 Secondary Efficacy Analyses  
Secondary analyses will evaluate a number of endpoints : 
• The proportion of SB623 treated subjects ( pooling both SB623 doses) that improve at 
least 1 point on the Modified Rankin Scale (mRS) will be analyzed  at 6 months (from 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 60 of 86 Baseline)  using a similar GLMM model to the primary efficacy analysis .  The 
GLMM model will include treatment (SB623 combined doses vs. sham surgical 
control), mRS baseline score and pooled surgical site as fixed effect s. 
• The proportion of SB623 treated subjects ( pooling both SB623 doses) that improve at 
least 6  points on the Action Research Arm Test will be compared to sham -surgery 
controls at 6 months (from Baseline) using a similar GLMM model to the primary 
efficacy analysis.  The GLMM model  will include treatment (SB623 combined doses 
vs. sham surgical control), ARAT baseline score and pooled surgical site as fixed 
effect s. 
• The proportion of SB623 treated subjects ( pooling both SB623 doses) that improve at 
least 1  functional level on Gait Ve locity will be compared to sham -surgery controls at 
6 months (from Baseline)  using a similar GLMM model to the primary efficacy 
analysis.  The GLMM model will include treatment (SB623 combined doses vs. sham surgical control), Gait Velocity  baseline score and pooled surgical site as fixed 
effect s. 
• The mean change in the two of the four  NeuroQOL subdomain T  scores  of SB623 
treated subjects ( pooling both SB623 doses) will be compared to sham -surgery 
controls at 6 months (from Baseline) using a mixed model repeated measures model (MMRM).   The two  subdomains include:  
o Upper Extremity Function (Fine Motor ADL)  
o Lower Extremity Function (Mobility)  
The MMRM model will include treatment, visit, pooled site,  corresponding baseline 
subdomain T score, and the treatmen t-by-visit interactions.
  Restricted Maximum 
Likelihood Estimation procedure will be employed using an unstructured covariance matrix .  Missing observations will not be imputed for this analysis . 
• The proportion of SB623 treated subjects (pooling both SB623 doses) scoring either 
7 (much better) or 6  (a little better, meaningful) on the Global Rating of Perceived 
Change by both Subject and Clinician will be compared to sham -surgery controls at 
6 months (from Baseline) using a logistic regression model with tr eatment (SB623 vs . 
sham placebo) and pooled center as the covariates.  The outcome variable of this 
analysis is a dichotomized variable based on of the Global Rating of Perceived 
Change score (≥6 vs. <6) . 
• All efficacy endpoints mentioned above will be anal yzed to assess the treatment 
difference between SB623 2.5 -million and 5 -million cells groups.  The s ame 
statistical methodologies  to evaluate SB623 combined doses vs. surgical sham control 
for each efficacy endpoint will be used. 
18.2.1.3 Exploratory Efficacy Analy ses 
The analyses of exploratory efficacy endpoints will be detailed in the SAP. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 61 of 86 18.2.1.4 Subgroup Analysis  
Inferential analyses will be performed on some subgroups of interest.  Details of the subgroup 
analyses will be included in the SAP.  
18.3 Analysis of Safety 
All safety analyses will be performed on the safety population. 
Adverse events (AEs), discontinuation due to AEs, and serious adverse events (SAEs) will be 
summarized by presenting, for each treatment group, the number and percentage of patients 
having any adverse event, having an adverse event in each system organ class and having each 
individual adverse event.  Adverse events will further be categorized for each individual AE by severity, relationship to study drug, and action taken.  Other information collec ted will be listed 
as appropriate .  The summary of AEs will be limited to treatment emergent AEs  (TEAEs) , which 
are defined as any adverse event with onset on or after the initiation of treatment or any adverse 
event already present that worsens in intensi ty following exposure to study treatment.  
Summary statistics for vital signs and laboratory values will be provided.   Vital signs and 
laboratory data will be summarized by presenting shift tables, by presenting summary statistics of raw data and change fro m baseline values (means, standard deviations, medians, ranges) and 
by the flagging of abnormal values in data listings.
 
18.4 Multiplicity Considerations  
There are no  multiplicity consideration s for this study.  
18.5 Missing Data 
Every effort will be made to reduce t he number of dropouts and to document reasons for 
dropping out.  
18.6 Pooling Strategy for Surgical Sites  
Some surgical sites may not have sufficient number of subjects for the efficacy analyses.  Small surgical sites  will be pooled by size within geographic region if necessary .  Details of the pooling 
will be described in the study statistical analysis plan (SAP) . 
18.7 Determination of Sample Size  
The sample size was estimated based on the primary efficacy endpoint , propor tion of re sponders, 
which is defined as ≥ 10 points on the FMMS, at Month 6 LOCF (last observation carried 
forward).  Based on the results on the Phase 1/2a study it was assumed that the responder rate 
was 33% for the SB623 treatment group.  Given high surg ical placebo response rates (Meissner 
et al., 2013) it was assumed that the responder rate in the surgical sham was 11.7% (i.e. 35% of 
the treatment responder rate) .  Assuming a 80% power, alpha level of 0.05 (two- tailed test), and 
2:1 (pooled SB623 t reatment s: sham control) ratio of randomization, a sample size of 
138 ( 92 subjects in treatment group and 46 subjects in control  group) is required to detect this 
21.3% difference in the proportion of FMMS responders .  Based on a 10%  upward adjustment to 
compensate for dropout patients, a total of approximately 156 subjects ( 104 treatment and 
52 control ) will be required .  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 62 of 86 18.8 Deviations from the Protocol Analysis Plan  
Any deviations from the original planned analysis as described in the protocol will be detail ed in 
the final integrated clinical report with an explanation of the alternative methods employed.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 63 of 86 19.0 ADMINISTRATION OF THE  STUDY 
19.1 Regulatory Considerations  
This study will be conducted in compliance with the protocol, ICH Good Clinical Practice 
Guidelines (G CPs), and the applicable local regulatory requirements.  This study will be 
conducted in accordance with the ethical principles that originate in the Declaration of Helsinki and ICH Guidelines for Good Clinical Practices (GCPs).  
Study protocols and Informe d Consent Forms will be approved by the appropriate Ethics 
Committee or Institutional Review Board (and governmental authorities, as needed) prior to initiation of the study at a particular site.  All patients will sign an Informed Consent Form prior to an y study- specific procedures.  Performance during the study will be routinely monitored by a 
study monitor selected by the Sponsor.  
19.2 Independent Ethics Committee (EC)/Institutional Review Board (IRB) 
The Investigator must submit the final protocol and propos ed informed consent document to an 
Independent Ethics Committee (EC) or Institutional Review Board (IRB) that complies with the 
ICH Guideline for Good Clinical Practice.  The EC/IRB will provide the Investigator with a 
written decision regarding the conduc t of the study at that site and a copy of the document will 
be forwarded to the Project Manager.  The study will not be initiated and patients will not be 
enrolled until the appropriate documentation of EC/IRB approval of the study protocol and the 
informe d consent has been received.  
Substantive modifications to the protocol will be submitted to the EC/IRB for approval.  These 
modifications may be implemented only after EC/IRB written approval has been received and 
forwarded to the Project Manager.  Adminis trative changes to the protocol such as a change that 
has no effect on the conduct of the study or risk to the patient should be submitted to the EC/IRB 
for review, but formal approval is not required.  
The Investigator must also submit any other written in formation that will be given to the study 
patients as well as any advertisements for patient recruitment, if used, to the EC/IRB for approval prior to implementing these documents.  
The Investigator will make appropriate and timely reports to the EC/IRB as required by 
applicable government regulations and EC/IRB policy.  In addition to progress reports, all 
known information regarding serious adverse events, whether observed at their clinical site or at 
another site participating in a clinical investigation with the Study Product , will be reported to 
the EC/IRB.  It is the Sponsor and/or its designee’s responsibility to inform the Investigator of 
serious adverse events observed at other investigational sites. 
It is the Investigator's obligation to provide the  Sponsor and/or its designees with copies of all 
study -related correspondence with the EC/IRB in a timely fashion and to retain originals in a file.  
This EC/IRB correspondence file will be made available as requested to appropriate designees 
for monitoring or quality assurance review and to governmental regulatory representatives during site audits.  
19.3 Patient Information and Informed Consent  
Written informed consent must be obtained from each patient after the nature of the study has been fully explained in accordance with the ICH Guideline for Good Clinical Practice.  Informed 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 64 of 86 consent must be obtained prior to performing any study -specific procedures.  The consent form 
that is used must be approved by both the reviewing EC/IRB and by the Sponsor. 
The patient  and the individual explaining the study will sign the current EC/IRB -approved 
version of the consent form.  A copy of the signed consent form will be given to the patient.  The 
date that consent was obtained will be recorded on the case report form as wel l as in the patient's 
chart.  
A copy of the EC/IRB -approved version of the consent form will be provided to the Sponsor.  
Original signed consent form must be maintained at the site and be made available for 
inspection, as appropriate. 
19.4 Adherence to the Prot ocol 
The study shall be conducted as described in this protocol except for an emergency situation in 
which proper care of the patient requires immediate alternative intervention.  This protocol refers 
to the protocol as provided by the Sponsor and approved by both the IRB and the FDA.  All of 
these versions of the protocol must be the same.  While FDA regulations permit the protocol to be amended, this must be done in accordance with the provisions noted in the Protocol 
Modifications section below .  Any dev iation from the design of the study as set forth in this 
document must be recorded as a protocol deviation and be explained in detail as it occurs and/or 
is detected.  
19.5 Protocol Modifications  
Neither the Investigators nor the Sponsor will modify this protocol without obtaining the concurrence of the other.  All protocol amendments will be issued by the Sponsor, and must be signed and dated by the Investigator prior to implementation of the amendment.  The Sponsor 
will submit protocol modifications to R egulatory Agencies as required.  The Investigator is 
responsible for notifying the EC/IRB of changes.  Substantive changes will require EC/IRB approval, such as changes in experimental procedures that affect patient safety, changes in 
dosage or study treat ment, changes in assessment parameters, or changes in patient eligibility 
criteria.  The EC/IRB may require the Informed Consent Form to be altered in the event of 
protocol changes or new safety information.  
In situations requiring a departure from the protocol, the Investigator or other physician in attendance will contact the Sponsor or designee by fax or telephone.  If possible, this contact will occur before implementing any departure from protocol.  In all cases, contact with the Sponsor 
or designee mu st be made as soon as possible in order to discuss the situation and agree on an 
appropriate course of action.  The CRF and source document must describe any departure from 
the protocol and the circumstances.  
19.6 Data Collection  
Patient screening/enrollment will be documented in a study -specific log at the study site.  This 
log will capture the following information: patient number, initials, patient personal identification number or medical record number, date of screen/enrollment, reason for not 
enrolling (if  applicable), and any comments.  
The results from Screening and data collected during the s tudy (except data that are 
electronically transferred ) will be recorded in the subject’s  electronic CRF .  The s tudy sites will 
use an EDC system (Medidata RAVE) that is compliant with relevant FDA regulatory 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 65 of 86 requirements per 21 CFR  Part 11.  Password protected access to the EDC system will be via a 
secure website.  Data queries and data corrections will be handled through the same system .  All 
transactions within the EDC system are fully documented within an electronic audit trail.  Each 
set of completed CRFs must be reviewed and electronically signed and dated by the Investigator.  
 
Upon further data processing, queries may be generated and sent to the Investigator  for 
clarification or correction.  The Investigator will address any queries and forward resolutions as 
directed by the site monitor.  
19.7 Computerized Systems Used for Source Data  
A list of the computerized systems that will be used to create, modify, maintain , archive, retrieve, 
or transmit source data are presented below, pursuant to the Guidance for Industry Computerized Systems Used in Clinical Investigations, May  2007. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 66 of 86 Table 5 : Computerized Systems Used for Source Data  
Protocol Step  Computerized System Type or 
Description  
Informed Consent  A 
Demographics  A 
Inclusion/Exclusion Review  A 
Eligibility Criteria Review  A 
Randomization  C 
Medical History  (including stroke history)  A 
Subject Exercise Diary  A 
Leg Activity Monitor  D 
Urine Pregnancy Test  A 
Serum Pregnancy Test  B 
Physical Examination  A 
Vital Sign Measurements  A 
Chest X -ray A 
12-lead ECG  D 
Clinical Laboratory Evaluation (Hematology and Serum 
Chemistry)  B 
INR B 
HLA Typing of each Subject  B 
ApoE4 & BDNF  Val66Met genotyping  B 
Occult Malignancy  B 
CESD -R Scale  A 
Head CT  A 
Imaging – Head MRI  D 
Imaging – Diffusion Tensor Imaging  D 
Modified Rankin Score  A 
Motricity Index  A 
Fugel -Meyer Motor Score  A 
ARAT  A 
Gait Velocity  A 
NeuroQoL (2 subdomains)  A 
Global Rating of Perceived Change (subject and 
clinician)  A 
Adverse Events  A 
Serum for anti -HLA Antibodies  B 
PBMC Sample  B 
Concomitant Medications  A 
Sham Surgery or Cell Administration  A 
Statistical Analysis  SAS®, version  9.4 or higher  
A = EDC ( Medidata RAVE ); B = LIMS; C  = IVRS; D  = Core Laboratory Overread . 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 67 of 86 19.8 Maintaining Records  
A study binder must be maintained at the investigative site for study documents, including a 
signed Investigator Agreement.  The Sponsor, or its designee, will provide a Study Binder to the 
site. 
According to U.S. Federal Regulations (21 CFR 312), all records related to this clinical trial must 
be retained by the Investigator for at least 15 years after the last approval of a marketing 
application and until there are no pe nding or contemplated marketing applications OR until at 
least 2  years have elapsed since the formal discontinuation of clinical development of the 
investigational product.  The Sponsor will inform the Investigator as to when these documents no 
longer need  to be retained.  These documents must be stored in a safe location and be available 
in the event of a regulatory audit. 
Study records that must be retained include, but are not necessarily limited to: patient charts, 
case report forms, product disposition records, essential documents, and study reports.  
19.9 Monitoring, Auditing, Inspecting  
The Sponsor or designee ( e.g., clinical research organization [CRO]) will assure the accuracy of 
data, the selection of qualified Investigators, appropriate study centers and review protocol procedures with the Investigators and associated personnel prior to the study and during periodic 
monitoring visits.  The Sponsor or a designee will review CRFs for accuracy and completeness during on- site monitoring visits and via access  to the secure website.  Discrepancies will be 
resolved with the Investigator as appropriate.  
The Sponsor or its designees will monitor the study using the following methods:  
• telephone contacts  
• periodic site visits  
• review of original patient records, case report forms, drug accountability and storage, 
and general study documentation 
So that the study may be adequately monitored, the Investigator will cooperate in providing the 
Sponsor’s designees with all study documents (e.g., patient charts and study file s) and 
responding to inquiries that may arise as a result of the document review.  
Review of these documents will usually occur during a routine monitoring visit, but may also be required during a visit by a quality assurance auditor.  The Investigator will  also provide access 
to these records to regulatory representatives if and when requested.  The Sponsor reserves the 
right to terminate the study site if access to source documentation of work performed in this 
study is denied to the Sponsor or regulatory representatives.  
19.10 Confidentiality  
The anonymity of patients participating in this study must be maintained.  Patients will be 
identified by their assigned patient number and their initials in all written communications 
between the Investigator and Sponsor.  Documents that are not submitted to the Sponsor and that 
identify the patient ( e.g., signed informed consent; source documents/charts) will be made 
available to the Sponsor or regulatory authorities for inspections, but will be maintained in 
confidence.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 68 of 86 All study related information provided by the Sponsor to the Investigator and not previously 
published, including but not limited to the active study agent identity, the investigator's brochure, 
the study protocol, verbal and written communication, case re port forms, assay methods and 
scientific data, will be considered confidential.  In addition, all information developed during the 
conduct of the clinical investigation of the study agent is also considered confidential.  Neither 
the Investigator nor any of his/her employees or agents shall disclose or use this information for 
any purpose other than the performance of the clinical study.  Such information shall remain the confidential and proprietary property of the Sponsor, and disclosure to others will be  limited to 
other physicians who are conducting studies with the same active study agent, the Ethics Committee/IRB and the applicable regulatory authorities except by prior written permission of the Sponsor or its agents.  At such time that information bec omes widely and publicly available 
through no fault of the Investigator, the obligation of nondisclosure toward that particular information will cease.  
19.11 Publication Policy  
Publication of the results of this study may be appropriate.  At least 30 days prior to expected 
submission to the intended publisher or meeting committee, the Investigator must submit a copy of the desired presentation (oral or written) or publication manuscript to the Sponsor.  This review period may be shortened upon mutual consent wher e circumstances require expeditious 
review.  The Sponsor reserves the right to suggest modification of any publication, presentation or use by the Investigator if such activity may jeopardize a patent application, an existing patent, or other proprietary r ights .  Individual investigators will not publish details of specific subjects 
separately from the r esults of the entire trial.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 69 of 86 20.0 APPENDIX A: JUSTIFICATION FOR S TUDY ENDPOINTS  
To overcome the perceived limitations of composite scales or global measures of di sability, 
several narrow domain outcome measures have been devised, validated and applied to the 
assessment of clinical recovery in the chronic stroke setting .  These narrow domain outcome 
measures fall along a continuum of measurement moving from measurem ents at the level of 
body function or structure to those focused on participation and life satisfaction.1  Consistent 
with the WHO ICF conceptual framework, we propose using narrow domain outcome measures 
that address the three primary levels of human functioning – the body or body part, the whole 
person and the whole person in relation to his/her social context.1  Given that the focus of SB623 
is to treat chroni c stroke patients with persistent deficits in the motor  domain of neurological 
function, the outcome measures we propose to use in our P2b study include:  
 
• Impairment (or Body Function/ Structure): Fugl -Meyer Motor Scale (Primary Endpoint)  
• Disability (or Ac tivity):  
o Upper Extremity Motor – Action Research Arm Test (Secondary Endpoint)  
o Lower Extremity Motor – Gait Velocity (Secondary Endpoint)  
• Handicap (Participation/ Life Satisfaction): NeuroQOL subdomains (Secondary Endpoints)  -  
o Upper Extremity Function  
o Lower Extremity Function  
 
20.1 Justification for use of the Fugl -Meyer Motor Scale as primary endpoint  
The F -M scale was developed specifically because prior scales focused on ADLs and measures 
of global function and not on specific improvements in the neuromuscul ar function of the 
affected limb .  The need that gave rise to the F-M scale was for a specific and quantitative 
method for measuring recovery from hemiplegia.2  The F -M scale is now one of the most widely 
recognized and clinically relevant measures of body function impairment after stroke.3 The 
motor component of the F-M scale in particular has well -established reliability and validity 
across different stroke recovery time points including chronic stroke.2, 4 
The F -M scale assesses several dimensions of impairment, including range of motion, pain, 
sensation, upper extremity, lower extremity, and balance.5  The specific items in the upper -
extremity subsections were derived from the Brunnstrom’ s stages of post -stroke motor recovery.6 
The items of the F -M are mainly scored on a 3 -point Likert -type ordinal scale, from 0 to 2 
applied to each item, and the items are summed to provide a maximum score of 226.  The motor domain includes items measuring movement, co ordination, and reflex action about the shoulder, 
elbow, forearm, wrist, hand, hip, knee, and ankle .  The motor score ranges from 0  (hemiplegia) 
to a maximum of 100 points (normal motor performance).
2  The F-M motor component c onsists 
of the 33- item upper -extremity subscale (UE -FM) and the 17- item lower -extremity subscale 
(LE-FM).5  The UE -FM ranges from 0 to 667 and the LE -FM from 0 -34.  The use of these 
subscales can be used alone to lessen the patient burden of the full questionnaire .  For example, 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 70 of 86 many of the chronic stroke studies described below use the UE -FM alone to evaluate the specific 
effects of therapeutic interventio n on upper limb motor function. 
The F -M scale assesses several impairment dimensions and has been extensively used in studies 
with chronic stroke patients .  In fact, in a systematic review of RCTs examining robot assisted 
therapy in chronic stroke, 60% of the RCTs included in analysis used the F -M scale as the 
primary outcome parameter.8  More recent RCTs investigating the use of patients continue to use 
the F -M motor scale as the primary outcome measure.9-12  Other studies include constraint 
induced therapy trials13, 14, brain- machine interface15, transcutaneous electrical nerve stimulation 
(primary outcome measure)16, 17 and mirror therapy (primary outcome measure in this 33 patient 
RCT) .18 
20.2 Rationale for Narrow Domain Outcome Measures in Chronic Stroke Patients with 
Motor Deficit  
The neurological de ficit associated with stroke depends on the location, extent and pattern of 
resolution of the infarction.  Deficits can involve different neurological domains such as: motor, 
sensory, cognitive, attention, language, visual, coordination and gait .  These domain specific 
deficits can occur alone or in combination .  Each of these domains can dominate the clinical 
presentation of stroke to a greater or lesser extent and may demonstrate different patterns of recovery.
19 
In contrast to acute stroke, the chronic phase of stroke recovery is associated with incremental 
improvements in neurological function that typically occur asymmetrically in time and extent 
across these different domains .  Often the magnitude of clinical improvement seen in chronic 
stroke patients is less than in the acute stroke phase and therefore require the use of outcome 
measures s pecific to the neurological domain of interest in order to detect  clinically meaningful 
change.  
Several narrow domain outcome measures have been devised, validated and applied to the assessment of clinical recovery in the chronic stroke setting .  These nar row domain outcome 
measures fall along a continuum of measurement moving from measurements at the level of 
body function or structure to those focused on participation and life satisfaction.
1 
Justification for the specific choice of the Action Research Arm Test (ARAT) and Gait Velocity 
as narrow domain outcome measures that assess changes in the level of disability  in the upper 
and lower extremity respectively of chronic stroke patients with mo tor deficits is provided 
below. 
20.3 Justification for use of the Action Research Arm Test (ARAT) as a secondary 
endpoint  
The ARAT is an observer -rated, performance- based assessment of upper extremity function and 
dexterity among individuals who sustained cortical damage resulting in hemiplegia.20, 21  It has 
been used extensively to measure ch anges in upper extremity disability following a variety of 
therapeutic interventions (e.g. mirror therapy, somatosensory stimulation, robot training, 
transcranial magnetic stimulation and constraint induced therapy) in chronic stroke patients.22-27  
This outcome measure specifically assesses a subject’s ability to handle objects differing in size, 
weight and shape and therefore can be considered to be an arm -specific measure of activity 
limitation.28  The ARAT consists of 19 items grouped into four hierarchical subsca les: grasp, 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 71 of 86 grip, pinch, and gross movement.29 Summation of a 0 -3 score in each item yields a total score 
between 0 and 57.1 
The ARAT provi des a specific assessment of arm function, including proximal control and 
dexterity and may be predictive of improvement in ADL outcomes.1  The ARAT appears to be 
reliable (r  = 0.98), valid (rho =  0.92) and r esponsive with adequate floor and ceiling effects (only 
12.5 to 17% of patients scoring the lowest or highest scores) in subjects with stroke .29 
The magnitude of change in the ARAT that is considered to be clinically meaningful differs 
according to the time post stroke .  According to Lang et al. patient expectations in the acute 
stroke setting are higher than in the chronic phase where patients may have a greater awareness 
of how smaller changes may be functionally beneficial and may have lower expectations for full 
recovery.30  In chronic stroke patients, a change of at least 6  points  on the ARAT has been 
selected as a clinically meaningful threshold.24, 31, 32  For example, Murphy et al. found that a 
decrease in movement time by 5 seconds d uring the drinking task is associated with 6 points  
improvement in ARAT score.33  This is consistent with the fact that change scores of 5 –10% of 
the scale range have been found to be clinically meaningful on a number of health related quality 
of life measures in a variety of patient populations.30 
20.4 Justification for use of Gait Velocity as a secondary endpoint  
Gait is commonly affected by stroke and Gait Velocity is a useful outcome measure of lower 
extremity function as walking speed predicts the level of disability.34, 35  as improvements are 
correlated with better quali ty of life.36 Furthermore, Gait Velocity measures are objective and 
have well defined t hresholds .  For example, in the context of chronic stroke, a gait velocity that 
is greater than 0.8 m/s is associated with full community mobility; 0.4 to 0.8  m/s is associated 
with short walks in the community; and gait velocity less than 0.4 m/s with mobility limited to 
the home.36 In the chronic stroke setting, improvements in gait veloci ty are known to be related 
to the baseline level of immobility .  Given this fact, the LEAPS trial measured the proportion of 
subjects that moved at least one functional level of walking.34, 37  A 20% difference between 
treatment groups was considered to be clinically meaningful.35  These transitions from one level 
to another are associated with improvements in home or community ambulation, functional status, and quality of life.
34  The minimal clinically important difference for improvement in gait 
velocity for subjects with subacute stroke is 0.16 m/s and based on the results of the LEAPS 
study there was no significant difference in improvement seen at 6 versus 12 months  post 
intervention.38 
20.5 Justification for use of NeuroQOL as a secondary endpoint  
Justification for choosing two specific NeuroQOL Domains as narrow domain outcome 
measures that assess changes in the level of Quality of Life, Satisfaction and Participation 
second ary to improvements in upper and lower extremity mot or function are provided below.  
To address existing limitations of Quality of Life (QOL) scales in neurology such as 
questionable validity, poor interpretability and disease specific applicability, the Na tional 
Institute of Neurological Disorders and Stroke devised the NeuroQOL.  NeuroQOL is a set of 
self-report measures that assesses the health -related quality of life (HRQOL) of adults and 
children with neurological disorders that includes stroke.39  As outlined in the NeuroQOL User 
Manual, NeuroQOL is comprised of item banks and scales that evaluate symptoms, concerns, and issues that have been validated for stroke and other neurological diseases .  The  domains 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 72 of 86 included in NeuroQOL were identified through several sources, including an extensive literature 
review, an on -line Request for Information (RFI), two phases of in- depth expert interviews 
(n = 44 and n = 89, respectively), patient and caregiver foc us groups (N  = 11 groups) and 
individual interviews with patients and proxies (N  = 63).  On the basis of this input, 17 Health-
Related QOL domains and sub- domains were chosen for adults .  Items were selected for 
inclusion in each domain through a multi -step, iterative process whereby candidate items were 
reviewed to ensure relevance, translatability, clarity and comprehensive content coverage.  The resultant sets of items (item pools) underwent calibration using Item Response Theory (IRT) 
analyses to form t he final item banks and scales .  The scales and short forms (8- 10 items) from 
each bank were subsequently validated in adult and pediatric clinical samples.
40  In short, the 
validity of the NeuroQOL measures for adults with stroke is supported with satisfactory internal consistency, test -retest reliability and  significant correlations with many external validity 
measures.  
20.6 Justification for choice of NeuroQOL Domains  
Neuro -QOL instruments were developed to be appropriate for a range of neurological conditions .  
They are not disease- specific measures .  Consequent ly, researchers will need to consider what 
domains of self -reported health are worth assessing within a given disease and within a given 
study methodology.
39  Given this study’s focus on improvements in motor function the following 
QOL Domains were chosen:  
• The Upper Extremity Domain of NeuroQOL measures one's ability to carry out various activities involving digital, manual and reach -related functions, ranging from fine motor to 
self-care (activities of daily living).  
• The Lower Extremity Domain of NeuroQOL measures one's ability to carry out various 
activities involving the trunk region and increasing degrees of bodily movement, ambulation, 
balance or endurance.  
 
References  Supporting Justification of Endpoints : 
 
1. Salter K, Campbell N, Richardson M, Mehta S, Jutai J, Moses M, et al. Outcome measures in stroke rehabilitation. Evidence- Based Review of Stroke Rehabilitation. 
2013;2014 
2. Gladstone DJ, Danells CJ, Black SE. The fugl -meyer a ssessment of motor recovery after 
stroke: A critical review of its measurement properties. Neurorehabilitation and Neural Repair . 2002;16:232- 240 
3. Sullivan KJ, Tilson JK, Cen SY, Rose DK, Hershberg J, Correa A, et al. Fugl -meyer 
assessment of sensorimotor function after stroke: Standardized training procedure for clinical practice and clinical trials. Stroke; a journal of cerebral circulation. 
2011;42:427- 432 
4. Duncan PW, Propst M, Nelson SG. Reliability of the fugl -meyer assessment of 
sensorimotor recovery following cerebrovascular accident. Physical therapy. 1983;63:1606- 1610 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 73 of 86 5. Fugl-Meyer AR, Jaasko L, Leyman I, Olsson S, Steglind S. The post -stroke hemiplegic 
patient. 1. A method for evaluation of physical performance. Scandinavian journal of 
rehabilitation medicine . 1975;7:13- 31 
6. Brunnstrom S. Motor testing procedures in hemiplegia: Based on sequential recovery stages. Physical therapy . 1966;46:357- 375 
7. Lin JH, Hsu MJ, Sheu CF, Wu TS, Lin RT, Chen CH, et al. Psychometric comparisons of 4 measures for assessing upper -extremity function in people with stroke. Physical 
therapy . 2009;89:840- 850 
8. Kwakkel G, Kollen BJ, Krebs HI. Effects of robot -assisted therapy on upper limb 
recovery after stroke: A systematic review. Neurorehabil Neural Repair . 2008;22:111-
121 
9. Lo AC, Guarino P, Krebs HI, Volpe BT, Bever CT, Duncan PW, et al. Multicenter randomi zed trial of robot -assisted rehabilitation for chronic stroke: Methods and entry 
characteristics for va robotics. Neurorehabil Neural Repair . 2009;23:775- 783 
10. Conroy SS, Whitall J, Dipietro L, Jones -Lush LM, Zhan M, Finley MA, et al. Effect of 
gravity o n robot -assisted motor training after chronic stroke: A randomized trial. Archives 
of physical medicine and rehabilitation. 2011;92:1754- 1761 
11. Lo Surdo JL, Millis BA, Bauer SR. Automated microscopy as a quantitative method to measure differences in adip ogenic differentiation in preparations of human mesenchymal 
stromal cells. Cytotherapy . 2013;15:1527- 1540 
12. Wu CY, Yang CL, Chuang LL, Lin KC, Chen HC, Chen MD, et al. Effect of therapist -
based versus robot -assisted bilateral arm training on motor contro l, functional 
performance, and quality of life after chronic stroke: A clinical trial. Physical therapy . 
2012;92:1006- 1016 
13. Page SJ, Sisto SA, Levine P. Modified constraint -induced therapy in chronic stroke. 
American journal of physical medicine & rehabilitation / Association of Academic Physiatrists . 2002;81:870- 875 
14. Page SJ, Sisto SA, Levine P, Johnston MV, Hughes M. Modified constraint induced therapy: A randomized feasibility and efficacy study. Journal of rehabilitation research and development . 2001;38:583- 590 
15. Ramos -Murguialday A, Broetz D, Rea M, Laer L, Yilmaz O, Brasil FL, et al. Brain-
machine interface in chronic stroke rehabilitation: A controlled study. Annals of neurology . 2013;74:100- 108 
16. Lindenberg R, Renga V, Zhu LL, Nair D, Schl aug G. Bihemispheric brain stimulation 
facilitates motor recovery in chronic stroke patients. Neurology . 2010;75:2176- 2184 
17. Kim TH, In TS, Cho HY. Task- related training combined with transcutaneous electrical 
nerve stimulation promotes upper limb functi ons in patients with chronic stroke. The 
Tohoku journal of experimental medicine . 2013;231:93- 100 
18. Wu CY, Huang PC, Chen YT, Lin KC, Yang HW. Effects of mirror therapy on motor and sensory recovery in chronic stroke: A randomized controlled trial. Archi ves of 
physical medicine and rehabilitation. 2013;94:1023- 1030 
19. Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality -specific outcome 
measures in clinical trials of stroke recovery -promoting agents. Stroke; a journal of 
cerebral circulation . 2007;38:1393- 1395 
20. Lyle RC. A performance test for assessment of upper limb function in physical rehabilitation treatment and research. International journal of rehabilitation research. 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 74 of 86 Internationale Zeitschrift fur Rehabilitationsforschung. Revue inter nationale de 
recherches de readaptation. 1981;4:483- 492 
21. Hsueh IP, Hsieh CL. Responsiveness of two upper extremity function instruments for 
stroke inpatients receiving rehabilitation. Clinical rehabilitation . 2002;16:617- 624 
22. Etoh S, Noma T, Ikeda K, Jonoshita Y, Ogata A, Matsumoto S, et al. Effects of repetitive trascranial magnetic stimulation on repetitive facilitation exercises of the hemiplegic hand in chronic stroke patients. Journal of rehabilitation medicine . 2013;45:843- 847 
23. Fleming MK, So rinola IO, Roberts -Lewis SF, Wolfe CD, Wellwood I, Newham DJ. The 
effect of combined somatosensory stimulation and task- specific training on upper limb 
function in chronic stroke: A double -blind randomized controlled trial. Neurorehabil 
Neural Repair . 2014 
24. Kitago T, Liang J, Huang VS, Hayes S, Simon P, Tenteromano L, et al. Improvement after constraint -induced movement therapy: Recovery of normal motor control or task-
specific compensation? Neurorehabil Neural Repair . 2013;27:99- 109 
25. Lin KC, Chen YT, Huang PC, Wu CY, Huang WL, Yang HW, et al. Effect of mirror therapy combined with somatosensory stimulation on motor recovery and daily function in stroke patients: A pilot study. Journal of the Formosan Medical Association = Taiwan yi zhi . 2014;113:422- 428 
26. Timmermans AA, Lemmens RJ, Monfrance M, Geers RP, Bakx W, Smeets RJ, et al. Effects of task -oriented robot training on arm function, activity, and quality of life in 
chronic stroke patients: A randomized controlled trial. Journal of neuroengineering and rehabilitation . 2014;11:45 
27. Page SJ, Levine P, Leonard A, Szaflarski JP, Kissela BM. Modified constraint -induced 
therapy in chronic stroke: Results of a single -blinded randomized controlled trial. 
Physical therapy . 2008;88:333- 340 
28. Platz T, Pink owski C, van Wijck F, Kim IH, di Bella P, Johnson G. Reliability and 
validity of arm function assessment with standardized guidelines for the fugl -meyer test, 
action research arm test and box and block test: A multicentre study. Clinical rehabilitation . 2005;19:404- 411 
29. Zipp GPS, J. E. Strokedge taskforce. 2011:1- 278 
30. Lang CE, Edwards DF, Birkenmeier RL, Dromerick AW. Estimating minimal clinically important differences of upper -extremity measures early after stroke. Archives of physical 
medicine and r ehabilitation . 2008;89:1693- 1700 
31. van der Lee JH, Wagenaar RC, Lankhorst GJ, Vogelaar TW, Deville WL, Bouter LM. Forced use of the upper extremity in chronic stroke patients: Results from a single -blind 
randomized clinical trial. Stroke; a journal of ce rebral circulation. 1999;30:2369- 2375 
32. van der Lee JH, Beckerman H, Lankhorst GJ, Bouter LM. The responsiveness of the action research arm test and the fugl -meyer assessment scale in chronic stroke patients. 
Journal of rehabilitation medicine . 2001;33:110- 113 
33. Alt Murphy M, Willen C, Sunnerhagen KS. Responsiveness of upper extremity kinematic measures and clinical improvement during the first three months after stroke. Neurorehabil Neural Repair . 2013;27:844- 853 
34. Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, et al. Body -
weight -supported treadmill rehabilitation after stroke. The New England journal of 
medicine. 2011;364:2026 -2036 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 75 of 86 35. Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, et al. Protocol for 
the locomotor experience applied post -stroke (leaps) trial: A randomized controlled trial. 
BMC neurology . 2007;7:39 
36. Cramer SC. Improving outcomes after stroke by leaps (locomotor experience applied post-stroke) and bounds. Stroke; a journal of cerebral circulation. 2011;42:3659- 3660 
37. Nadeau SE, Wu SS, Dobkin BH, Azen SP, Rose DK, Tilson JK, et al. Effects of task-specific and impairment -based training compared with usual care on functional walking 
ability after inpatient stroke rehabilitation: Leaps trial. Neurore habil Neural Repair . 
2013;27:370- 380 
38. Tilson JK, Sullivan KJ, Cen SY, Rose DK, Koradia CH, Azen SP, et al. Meaningful gait speed improvement during the first 60 days poststroke: Minimal clinically important difference. Physical therapy . 2010;90:196- 208 
39. (NINDS). NIoNDaS. User manual for the quality of life in neurological disorders (neuro-qol) measures. 2010  
40. Cella D, Lai JS, Nowinski CJ, Victorson D, Peterman A, Miller D, et al. Neuro- qol: Brief 
measures of health -related quality of life for clinical research in neurology. Neurology . 
2012;78:1860- 1867 
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 76 of 86 21.0 APPENDIX B : WHO STANDARD T OXICITY C RITERIA 
The WHO Standard Toxicity Criteria is tabulated below in Table 6.  
Copies of this document will also be provided to each site as part of the study documents. 
For abnormalities not found elsewhere in the WHO table, use the following scale to assign grade 
or severity:  
Grade 1  Mild  Transient of mild discomfort; no limitation in activity; 
no medical intervention/therapy required.  
Grade 2  Moderate  Mild -to-moderate limitation in activity; some 
assistance may be need.  No or minimal medial 
intervention/therapy required.  
Grade 3  Severe  Marked limitation in activity, some assistance usually 
required; medical intervention/therapy required; 
hospitalization or prolongation of current 
hospitalization possible.  
Grade 4  Life-threatening  Extreme limitation in activity,  significant assistance 
required; significant medial intervention/therapy 
required; hospitalization or prolongation of current 
hospitalization or hospice care probable.  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 77 of 86 Table 6:  WHO (World Health Organization) Toxicity Criteria by Grade  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Haematology  WBC (x103/l)  4  3.0 - 3.9  2.0 - 2.9  1.0 - 1.9  < 1.0  
Haematology  Platelets (x103/l)  WNL  75.0 - normal  50.0 -  74.9  25.0 -  49.9  < 25.0  
Haematology  Haemoglobin (g/dl)  WNL  10.0 - normal  8.0 - 9.9  6.5 - 7.9  < 6.5  
Haematology  Granulocytes/ Bands 
(x103/l)  2  1.5 - 1.9  1.0 - 1.4  0.5 - 0.9  < 0.5  
Haematology  Lymphocytes 
(x103/l)  2  1.5 - 1.9  1.0 - 1.4  0.5 - 0.9  < 0.5  
Haematology  Haemorrhage  none  mild, no  gross, 1 -  2 units 
transfusion per episode  gross, 3 -  4 units 
transfusion per 
episode  massive, > 4 units 
transfusion per episode  
Coagulation  Fibrinogen  WNL  0.99 - 0.75 x N  0.74 -  0.50 x N  0.49 -  0.25 x N  < 0.25 x N  
Coagulation  Prothrombin 
time(Quick)  WNL  1.01 - 1.25 x N  1.26 -  1.50 x N  1.51 -  2.00 x N  > 2.00 x N  
Coagulation  Partial 
thromboplastin time  WNL  1.01 - 1.66 x N  1.67 -  2.33 x N  2.34 -  3.00 x N  > 3.00 x N  
Metabolic  Hyperglycaemia 
(mg/dl)  < 116  116 - 160  161 -  250  251 -  500  > 500 or ketoacidosis  
Metabolic  Hypoglycaemia 
(mg/dl)  > 64  55 - 64  40 - 54  30 - 39  < 30  
Metabolic  Amylase  WNL  < 1.5 x N  1.5 - 2.0 x N  2.1 - 5.0 N  > 5.0 x N  
Metabolic  Hypercalcaemia 
(mg/dl)  < 10.6  10.6 - 11.5  11.6 -  12.5  12.6 -  13.4  13.5  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 78 of 86 Table 6:  WHO (World Health Organization) Toxicity Criteria by Grade  (Continued)  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Metabolic  Hypocalcaemia 
(mg/dl)  > 8.4  8.4 - 7.8  7.7 - 7.0  6.9 - 6.1  6  
Metabolic  Hypomagnesaemia 
(mg/dl)  > 1.4  1.4 - 1.2  1.1 - 0.9  0.8 - 0.6  0.5  
Gastrointestinal  Nausea  none  able to eat 
reasonable intake  intake significantly 
decreased but can eat  no significant intake  __  
Gastrointestinal  Vomiting  none  1 episode in 24 hrs  2 - 5 episodes in 24 hrs  6 - 10 episodes in 
24 hrs  > 10 episodes in 24 hrs 
or requiring parenteral 
support  
Gastrointestinal  Diarrhoea  none  increase of 2 - 3 
stools / day over pre -
Rx  increase of 4 -  6 stools 
/ day, or nocturnal stools, or moderate 
cramping  increase of 7 -  9 
stools / day, or 
incontinence, or 
severe cramping  increase of > 10 stools / day or grossly bloody 
diarrhoea, or need for 
parenteral support  
Gastrointestinal  Stomatitis  none  painless ulcers, 
erythema, or mild 
soreness  painful erythema, 
oedema, or ulcers but 
can eat solids  painful erythema, oedema, or ulcers 
and cannot eat 
solids  requires parenteral or enteral support for 
alimentation  
Liver  Bilirubin (N = 17 
µmol/L)  WNL  -----  < 1.5 x N  1.5 - 3.0 x N  > 3.0 x N  
Liver  Transaminase 
(SGOT, SGPT)  WNL  2.5 x N  2.6 - 5.0 x N  5.1 - 20.0 x N  > 20.0 x N  
Liver  Alk Phos or 5 
nucleotidase  WNL  < 2.5 x N  2.6 - 5.0 x N  5.1 - 20.0 x N  > 20.0 x N  
Liver  Liver - clinical  No change 
from baseline  -----  -----  precoma  hepatic coma  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 79 of 86 Table 6:  WHO (World Health Organization) Toxicity Criteria by Grade  (Continued)  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Kidney, bladder  Creatinine  WNL  < 1.5 x N  1.5 - 3.0 x N  3.1 - 6.0 x N  > 6.0 x N  
Kidney, bladder  Proteinuria  No change  1 (+) or < 0.3 g% or 
3 g/L  2 - 3 (+) or 0.3 -  1.0 
g% or 3 -  10 g/L  4 (+) or > 1.0 g% 
or > 10g/L  nephrotic syndrome  
Kidney, bladder  Haematuria  Negative  microscopic only  gross, no clots no Rx 
needed  gross and clots bladder irrigation  requires transfusion or cystectomy  
Kidney, bladder  Weight gain/ loss  < 5.0 %  5.0 - 9.9 %  10.0 -  19.9 %  20.00%  -----  
Pulmonary  Pulmonary  none or no 
change  asymptomatic, with 
abnormality in PFTs  dyspnoea on significant exertion  dyspnoea at 
normal level of 
activity  dyspnoea at rest  
Cardiac  Cardiac arrhythmias  none  asymptomatic, 
transient, requiring 
no therapy  recurrent or persistent, no therapy required  requires treatment  requires monitoring; or 
hypotension, or 
ventricular tachycardia or 
fibrillation  
Cardiac  Cardiac function  none  asymptomatic, 
decline of resting 
ejection fraction by 
less than 20 % of 
baseline value  asymptomatic, decline of resting ejection 
fraction by more than 
20 % of baseline value  mild CHF, 
responsive to 
therapy  severe of refractory CHF  
Cardiac  Cardiac isc haemia  none  non-specific T - wave 
flattening  asymptomatic, ST and 
T wave changes 
suggesting ischaemia  angina without 
evidence of 
infraction  acute myocardial 
infarction  
Cardiac  Cardiac - pericardial  none  asymptomatic 
effusion, no 
intervention required  pericarditis (rub, chest 
pain, ECG changes)  symptomatic 
effusion; drainage 
required  tamponade; drainage urgently required  
 
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 80 of 86 Table 6:  WHO  (World Health Organization) Toxicity Criteria by Grade  (Continued)  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Cardiac  Hypertension  none or no 
change  asymptomatic, 
transient increase by 
greater than 20 mm 
Hg (D) or to >  150 / 
100 if previously 
WNL. No treatment 
required.  recurrent or persistent 
increase by greater 
than 20 mm HG (D) or 
to > 150 / 100 if previously WNL. No 
treatment required.  requires therapy  hypertensive crisis  
Cardiac  Hypotension  none or no 
change  changes requiring no 
therapy (including 
transient orthostatic 
hypo -tension)  requires fluid replacement or other 
therapy but not 
hospitalisation  requires therapy 
and 
hospitalisation; 
resolves within 48 
hours of stopping 
the agent  requi res therapy and 
hospitalisation for > 48 hrs after stopping the agent  
Neurologic  Neuro: sensory  none or no change  mild paraesthesias; 
loss of deep tendon 
reflexes  mild or moderate objective sensory loss 
moderate paraesthesias  severe objective 
sensory loss or 
paraesthesias that 
interfere with 
function  -----  
Neurologic  Neuro: motor  none or no 
change  subjective weakness; 
no objective findings  mild objective 
weakness without 
significant impairment 
of function  objective weakness 
with impairment of 
function  paralysis  
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 81 of 86 Table 6:  WHO (World Health Organization) Toxicity Criteria by Grade  (Continued)  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Neurologic  Neuro: cortical  none  mild somnolence or 
agitation  moderate somnolence 
or agitation  severe 
somnolence, (>50 
% waking hours), 
agitation, 
confusion, 
disorientation or 
hallucinations  coma, seizures, toxic 
psychosis  
Neurologic  Neuro: cerebellar  none  slight incoordination, 
dysdiadochokinesia  intention tremor, 
dysmetria, slurred 
speech, nystagmus  locomotor ataxia  cerebellar necrosis  
Neurologic  Neuro: mood  no change  mild anxiety or 
depression  moderate anxiety or 
depression  severe anxiety or depression  suicidal ideation  
Neurologic  Neuro: headache  none  mild  moderate or severe but 
transient  unrelenting and 
severe  -----  
Neurologic  Neuro: constipation  none or no change  mild  moderate  severe  ileus > 96 hrs  
Neurologic  Neuro: hearing  none or no 
change  asymptomatic, 
hearing loss on 
audiometry only  tinnitus  hearing loss interfering with 
function but 
correctable with 
hearing aid  deafness not correctable  
Neurologic  Neuro: vision  none or no 
change  -----  -----  symptomatic 
subtotal loss of 
vision  blindness  
Pain  Pain  none  mild  moderate  severe  reg. narcotics  
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 82 of 86 Table 6:  WHO (World Health Organization) Toxicity Criteria by Grade  (Continued)  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Skin  Skin  none or no 
change  scattered macular or 
papular eruption or 
erythema that is 
asymptomatic  scattered macular or 
papular eruption or 
erythema with pruritus 
or other associated 
symptoms  generalised 
symptomatic 
macular, papular 
or vesicular 
eruption  exfoliative dermatitis or ulcerating dermatitis  
Alopecia  Alopecia  no loss  mild hair loss  pronounced or total 
hair loss  -----  -----  
Allergy  Allergy  none  transient rash, drug 
fever < 38o C (100.4o 
F)  urticaria, drug fever 38
o C (100.4o F), mild 
bronchospasm  serum sickness, 
bronchospasm 
requiring 
parenteral 
medication  anaphylaxis  
Local  Local  none  pain  pain and swelling with 
inflammation or 
phlebitis  ulceration  plastic surgery indicated  
Fever of 
unknown origin  Fever of unknown 
origin  none  37.1 - 38.0o C 98.7o - 
100.4o F  38.1 -  40.0o C 100.5o - 
104o F  > 40.0o C > 104.0o 
F for less than 24 
hrs  > 40.0o C (>104o F) for 
more than 24 hrs or 
accompanied by 
hypotension  
Infection  Infection  none  mild  moderate  severe  life-threatening  
Additional 
events  Asthenia  Analogous to Karnofsky 
index (WHO 
grading)              
Additional 
events  Chills  Analogous to fever              
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017   Page 83 of 86 Table 6:  WHO  (World Health Organization) Toxicity Criteria by Grade  (Continued)  
Category  Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Additional 
events  Peripheral oedema  analogous to 
weight gain              
Additional 
events  Anorexia  analogous to weight loss              
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 84 of 86 22.0 APPENDIX C: ANTICOAG ULANT GUIDELINES  
The use of antiplatelet, anti -coagulant, or non- steroidal anti- inflammatory drugs during the 
conduct of this study will be in accordance with the ACCP 2012 guideline “Perioperative 
Managem ent of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of 
Thrombosis, 9th Edition: American College of Chest Physicians Evidence -Based Clinical 
Practice Guidelines”. In summary the following should apply:  
 
• Prospective patients that are taking  Warfarin regularly should stop taking Warfarin 
5 days before  the surgery  visit. These patients should re -start Warfarin after surgery 
as appropriate.  
• INR will need to be repeated prior to surgery to confirm patient is off Warfarin (likely 
performed at the  hospital where the surgery is being performed)  
• All other anti- platelet drugs (including NSAIDs) should be stopped 7 days prior to 
surgery  
• Patients at high risk for Venous Thromboembolism (VTE) should be covered with 
prophylactic Low Molecular Weight Hep arin (e.g. Lovenox).  
• Anticoagulants (including antiplatelet or non -steroidal anti- inflammatory drugs 
(NSAIDs) should not be recommenced until Day 8 per the protocol unless the patient 
is at high risk for VTE in which use of LMWH only on postop Day  2 is ac ceptable.  
• Other than patients at high risk of VTE, no antiplatelet, anti -coagulant, or non-
steroidal anti- inflammatory drugs are to be restarted post- surgery until after the Day  8 
MRI is read and are determined to be safe to re- start 
  
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 85 of 86 23.0 REFERENCES  
                                                 
1  Warlow C, Sudlow  C, Dennis M, Wardlow J, and Sandercock P. Stroke. Lancet. 2003;  
362:1211–1224. 
2  Naidech AM and Weisberg LA, Treatment of chronic hypertension for the prevention of 
stroke, South Med J  96 (2003) (4), pp. 359–362.  
3  Ingall TJ, Preventing ischemic stroke current approaches to primary and secondary prevention, Postgrad Med 107 (2000) (6), pp. 34– 50. 
4  Caplan LR, Now is an exciting time to care for stroke patients, South Med J  2003; 96:329–
330. 
5  American Heart Association, Heart disease and stroke statist ics 2007 update. Circ.  2007; e99. 
6  Leary MC and Saver JL. Incidence of silent stroke in the United States  (2001) Poster 
presented at the 26th American Heart Association Stroke Meeting, February, Fort Lauderdale, Fla. 
7  Zweifler RM. Management of Acute S troke, South Med J  96 (2003) (4), pp. 380–385. 
8  American Heart Association, Heart Disease and Stroke Statistics —2007 Update. Circulation . 
2007; 115:e69- e171.  
9  Kreisel SH, Hennerici MG, and Bäzner  H. Pathophysiology of Stroke Rehabilitation: The 
Natural Course of Clinical Recovery, Use- Dependent Plasticity and Rehabilitative Outcome. 
Cerbrovasc Dis . 2007; 23:243- 255. 
10  Duncan PW, et al . Measure of Motor Recovery after Stroke. Outcome Assessment an d 
Sample Size Requirements. Stroke.  1992; 23:1084- 1089. 
11  Hendricks HT, et al. Arch Phys Med Rehabil . 2002; 83:1629- 1637. 
12  Jergensen HS, et al. Outcome and Time Course of Recovery in Stroke. Part II: Time Course 
of Recovery. The Copenhagen Stroke Study. Arch Phys Med Rehabil . 1995; 76:408- 412. 
13 Dobkin BH. Strategies for stroke rehabilitation. Lancet Neurol. 2004; 3: 528- 36. 
14  Smith WS, Hauser SL, Easton JD. Cerebrovascular Diseases. In: Braunwald E, Hauser S, Fauci AS, Longo DL, Kasper DL, Jameson JL, editors. Harrison’s Principles of Internal 
Medicine. 15
th ed. New York: McGraw -Hill; 2001. 
15  Engelstein E, Margulies J, and Jeret JS. Lack of t -PA use for acute ischemic stroke in a 
community hospital high incidence of exclusion criteria, Am J Emerg Med  18 (2000), pp. 
257–260 
16  Kreisel SH, Hennerici MG, and Bäzner H. Pathophysiology of Stroke Rehabilitation: The Natural Course of Clinical Recovery, Use- Dependent Plasticity and Rehabilitative Outcome. 
Cerbrovasc Dis . 2007; 23:243- 255. 
17  Bliss T, Guzman R, Daadi M, Steinberg GK. Cell Transplantation Therapy for Stroke. Stroke . 
2007; 38(part 2:817- 826. 
 
SanBio, Inc.   Confidential and Proprietary  
 
Protocol SB -STR02 05  January 2017  Page 86 of 86                                                                                                                                                              
18  Kondziolka D, Wechsler L, Achim C. Neural Transplantation for Stroke. J Clin Neurosci . 
2002; 9:225- 230. 
19  Savitz SI, Dinsmore JH, et al . Cell Therapy for Stroke. NeuroRx . 2004; 1:406- 414. 
20  Isacson O, Deacon TW, et al. Transplanted Xenogeneic Neural Cells in Neurodegenerative 
Disease Models Exhibit Remarkable Axonal Target Specificity and Distinct Growth Patterns of Glial and Axonal Fibres. Nat Med . 1998; 1:1189- 1194 
21  Deacon TW, Pakzaban P, et al.  Cytoarchitectonic Development, Axon- Glia Relationships, 
and Long Distance Axon Growth of Porcine Striatal Xenografts in Rats. Exp.  Neurol. 1994; 130:151- 167. 
22  Dinsmore JH, Martin J, et al . CNS Grafts for Trea tment of Neurologic Disorders. In: Methods 
of Tissue Engineering, Ed 1 pp 1127- 1134. San Diego: Academic Press, 2002. 
23  Borlongan CV, et al. Transplantation of Cryopreserved Human Embryonal Carcinoma -
Derived Neurons (NT2N Cells) Promotes Functional Recove ry in Ischemic Rats. Exp Neurol. 
1998; 149:310- 321. 
24  Kondziolka D, Wechsler L, et al.  Transplantation of Cultured Human Neuronal Cells for 
Patients with Stroke. Neurobiol. 2000; 55:565- 569. 
25  Kondziolka D, Steinberg GK, Wechsler L, et al. Neurotransplantation for Patients with 
Subcortical Motor Stroke: A Phase 2 Randomized Trial. J Neurosurg. 2005; 103:38- 45. 
26  Lunsford LD, Niranjan A, Khan AA, Kondziolka D. Establishing a Benschmark for Complications Using Frame -Based Stereotactic Surgery. Sterotact Fu nct Neurosurg. 2008; 
86:278- 287. 
27  Dezawa M, Kanno H, Hoshino M, et al.  Specific Induction of Neuronal Cells from Bone 
Marrow Stromal Cells and Application for Autologous Transplantation. J Clin Invest . 2004; 
113:1701- 1710. 
28  Page SJ, Fulk GD and Boyne P .  Clinically Important Differences for the Upper -Extremity 
Fugl-Meyer Scale in People with Minimal to Moderate Impairment Due to Chronic Stroke.  
Phys Ther .  2012; 92: 791- 8. 
29  Hantson L, et al .  The European Stroke Scale.  American Heart Association, Inc . 1994; 2215-
2219. 
30  Govan L, et al.  Categorizing Stroke Prognosis Using Different Scales. Stroke 2009; 40: 3396-
3399. 